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CHAPTER ONE 
REVIEW OF LITERATURE 
Extra-Cellular Membrane Fusion 
Intra- and inter-cellular communications are essential for life.  In some 
circumstances, communications are mediated by the transfer of hydrophilic molecules 
(1, 2).  The lipid membranes that line our cells and organelles, due to their hydrophobic 
cores, prevent these hydrophilic molecules from being readily transferred.  To 
successfully transfer hydrophilic cargos, membrane-enclosed compartments separate 
and unite through dynamic, flexible fission and fusion reactions (2–5).  These catalyzed 
processes are central to organelle and organismal biogenesis and communication.   
Intra-cellular membrane fusions are often utilized by cells to traffic 
macromolecules between organelles.  The molecular details of these intracellular 
fusions are relatively well understood, and rely on membrane proteins extending into the 
cytoplasm to catalyze membrane mergers, facilitating cargo transfers between 
compartments (2).  Extra-cellular membrane fusions, catalyzed by membrane proteins 
extending into the extracellular space, are also central to several biological processes.  
Enveloped viruses enter cells through membrane fusions (5).  Extracellular vesicles 
(EVs) released from cells also transfer proteins and nucleic acids between cell 
cytoplasms, presumably through membrane fusion (3, 4).  Even entire cells can fuse 
together, generating essential biological structures, as discussed below (6). While the 
ability to mediate extracellular membrane fusion is conserved amongst all eukaryotes 
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(7), and possibly all life (8), the molecular details of these extracellular fusions 
are often not well understood.  Further elucidation of extracellular membrane fusion 
mechanisms is required to better control these fusion events in health and disease. 
Steps in Membrane Fusion 
The main constituents of biological membranes are amphipathic phospholipids, 
each of which are composed of a hydrophilic head group and two hydrophobic tails.  In 
aqueous environments, hydrophobic interactions between phospholipid tails facilitate 
lipid aggregation into a semi-permeable bilayer with the hydrophobic tails of each leaflet 
facing each other.  Many hydrophilic molecules cannot penetrate the hydrophobic cores 
of these membranes.  Where hydrophilic molecules are contained exclusively within 
cell- and organelle-limiting membranes, fusion between distinct lipid bilayers is required 
to transport these molecules between cells.   
 Current models of membrane fusion indicate that fusion takes place in several 
steps (9) (Figure 1).  First, membranes are brought into close proximity.  Outward, 
“positive” curvatures in the bilayers facilitate these close interactions (10).  Upon coming 
into close proximity, the proximal leaflets of the bilayers merge, forming a hemifusion 
intermediate (11).  In this hemifused state, the distal leaflets of the two bilayers remain 
distinct, preventing the mixing of compartment lumens.  Finally, the merger of distal 
membrane leaflets leads to the formation of an aqueous pore.  Pore stabilization and 
expansion culminates in the mixing of internal contents between the now joined 
compartments. 
While membrane fusion is thermodynamically favorable, there are high kinetic 
barriers to the fusion process.  Cells and enveloped viruses have evolved to utilize a 
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variety of lipids and membrane proteins to reduce these energy barriers and render 
membranes permissive for fusion (5, 9, 12, 13).  In many contexts, however, these 
membrane fusion catalysts remain to be identified and characterized. 
Figure 1. Steps in Membrane Fusion. Fusion takes place in several steps.  First, 
opposing membranes (grey lipids) are brought into close proximity, likely aided by 
positive membrane curvatures away from compartment lumens (blue and red).  Then, 
outer leaflets of the membrane merge, forming a hemifusion intermediate.  Finally, distal 
leaflets merge, allowing for the mixing of compartment lumens (now purple). 
 
Viral Membrane Fusion 
The most well-studied membrane fusion processes occur during enveloped virus 
entry.  These viruses are encased by cell-limiting membranes during their egress from 
infected cells, and thus must fuse with target cell-limiting membranes to drive further 
infections.  Virus-cell membrane fusions are catalyzed by virus-encoded membrane 
fusion glycoproteins that are embedded in the virus envelope (5). During their 
production, virus fusion proteins are folded in such a way to store all of the energy 
required for fusion catalysis.  This energy is stored through intramolecular interactions 
(14), or through interactions with other viral proteins (15).  To catalyze membrane 
fusion, fusion proteins are “activated” to undergo enormous conformational changes 
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that release the energy required to drive membrane merger (5, 14, 16, 17).  They first 
unfold into long extended intermediates, exposing hydrophobic fusion peptides (FPs) 
that embed into the core of the opposing lipid bilayer.  These extended intermediates 
then refold, pulling virus and cell membranes together and catalyzing membrane 
merger. 
All characterized virus membrane fusion proteins are not enzymatic, and thus 
their activation must be tightly controlled to prevent untimely unfolding.  To provide this 
control, fusion proteins have evolved to utilize factors on target cells as “activators”, 
thereby isolating the fusion process to target cell membranes (5).  “Activators” directly 
engage membrane fusion proteins, and this engagement “triggers” fusion-catalyzing 
conformational changes.  Activators dictate cellular susceptibility to fusion, and can 
include cellular receptors, proteases, and cations.   
Coronavirus Membrane Fusion.   
Coronaviruses (CoVs) are enveloped, positive-sense RNA viruses that can 
cause mild and severe infections in the enteric and respiratory tracks of many mammals 
(18).  In humans, severe acute respiratory syndrome (SARS-) and Middle East 
respiratory syndrome (MERS-) CoVs can cause severe lung pathologies, especially 
amongst immunocompromised or co-morbid patients (19, 20).  CoV infections are 
mediated by trimeric, fusion-catalyzing spike (S) glycoproteins that extend ~10 nm from 
the virion surface (21).  To catalyze membrane fusion, CoV S proteins must engage 
multiple activators on the target cell (Figure 2).  In the case of MERS-CoV, dipeptidyl 
peptidase 4 (DPP4) receptors are the first activators that S proteins must encounter on 
the target cell (22).  MERS-CoV S (MERS-S) proteins engage DPP4s via their receptor 
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binding domains (23).  This engagement exposes sites on the S protein susceptible to 
cleavage by cellular proteases (24).  S protein proteolysis “triggers” the S protein to 
relocate its receptor binding domains and unfold into an extended intermediate 
structure.  Unfolding exposes hydrophobic fusion peptides that embed into the target 
cell membrane (25).  MERS-S proteins then refold, pulling virus and cell membranes 
closely together and facilitating their merger (26).  
 
Figure 2. Steps in Coronavirus Membrane Fusion. To catalyze membrane fusion and 
virus entry into host cells, MERS-CoV S (MERS-S) proteins (gray) bind dipeptidyl 
peptidase 4 (DPP4) receptors (purple) via their receptor-binding domains (green).  
Receptor engagement exposes substrates (blue stars) susceptible to cleavage by 
cellular proteases (blue).  Proteolytically- triggered MERS-S relocates its receptor 
binding domains and unfolds into an extended intermediate structure that embeds 
hydrophobic fusion peptides into target cell membranes.  Refolding of intermediates 
then pulls virus and cell membranes together to catalyze membrane fusion. 
CoV Entry Routes.   
Unlike most enveloped viruses, which enter cells in particular subcellular 
locations, CoVs have remarkable flexibility in the pathways they can take during entry 
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(27).  This is due to the ability of CoVs to utilize a variety of proteases as membrane 
fusion “triggers” (28–33).  Entry routes are thus dictated by the relative abundance of 
proteases on the cell surface and along the endocytic network.  Transmembrane 
proteases (TMPRs), such as transmembrane type II serine proteases (TTSPs), can 
cleave S proteins at or near the cell surface (30, 34, 35), while water-soluble cysteine 
cathepsin proteases can cleave S proteins in acidified endosomes (29, 31).  Therefore, 
in cells with high TMPR levels, S protein proteolysis occurs rapidly, leading to “early” 
entry at or near the cell surface (Figure 3, left panel).  In cells with low TMPR levels, 
CoVs are instead endocytosed before cathepsin-mediated proteolysis facilitates “late” 
entry from endosomes (Figure 3, right panel).   
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Figure 3. Proteases dictate CoV entry routes. (Left panel) When cell surface 
proteases, like TMPRs (blue), are present on the cell surface in sufficient abundance, 
MERS-S proteins bind DPP4 (purple) and quickly encounter triggering cleavages (blue 
stars).  Rapid cleavage facilitates “early” entry at or near the cell surface.  (Right panel) 
In the absence of cell surface proteases, MERS-S proteins are not efficiently triggered 
on the cell surface.  MERS-CoVs are instead endocytosed, where they encounter 
endosomal cathepsins (brown).  At low pH (yellow), cathepsins cleave MERS-S 
proteins, triggering inefficient “late” entry in the endosomal network.   
 
Serine protease inhibitors significantly reduce CoV titers in the lung, suggesting 
that early entry routes are also preferred in vivo (33), and that late entry may be 
relatively inefficient.  This may be due to CoVs encountering harsh, degradative 
environments in endosomes and lysosomes during late entry (36), as well as being 
exposed to endosome-localized antiviral factors (37).  However, there are also 
additional requirements imposed on CoVs during early entry. “Triggering” proteolytic 
cleavage sites on MERS-S are only exposed upon DPP4 engagement (28).  In addition, 
it is likely that multiple MERS-S proteins must be triggered to generate the forces 
required to catalyze membrane fusion (38).  DPP4 receptors and proteases must 
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therefore be in close proximity to facilitate efficient MERS-CoV entry into target cells.  
During “late” entry, water-soluble cathepsins likely have relatively easy access to DPP4-
bound MERS-S proteins.  In contrast, it is thought that transmembrane proteases are 
sequestered in membrane microdomains (39), and mislocalization can cause severe 
damage to cells and organisms (40).  TMPRs could therefore be scarce on most of the 
cell surface, making it unclear how DPP4-bound MERS-CoVs engage TMPRs 
efficiently. 
Extracellular Vesicles 
Virtually all cells can release membrane-enclosed extracellular vesicles (EVs) 
containing cytoplasmic proteins, nucleic acids, and small molecules (4, 41, 42).  EVs 
are formed by outward budding events at the plasma membrane (43), or by membrane 
budding into endosomes (44).  EVs are abundant in most biological fluids, with 
concentrations approaching one billion particles/mL in some cases (45).  When they 
were first observed in the early 1980s (43, 44, 46, 47), EVs were thought to function as 
cellular “garbage bags,” loaded with materials to be either expelled into the extracellular 
space or degraded in lysosomal compartments (44).  It is now clear, however, that EVs 
also play central roles in intercellular communication (1).  They do this by ferrying their 
cargos to other cells, changing how those cells behave (4, 41).  While the field of EV 
biology is nascent, it is growing exponentially, with thousands of articles documenting 
EV-mediated phenotypic changes to cells and organisms.  These articles indicate that 
EVs can regulate a variety of biological processes, including tumor growth and 
metastasis (48), lymphocyte activation (49, 50), innate immune responses (51), 
pathogenic infections (52), skeletal maintenance (53), and development (54). 
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EVs in Intercellular Communication.   
While many studies indicate that EVs play critical roles in health and disease, 
most investigations have focused on documenting EV phenotypic effects on cells and 
tissues.  Mechanistic insights into how EVs carry out these functions, however, are 
surprisingly lacking.  Several pioneering studies, however, have begun to expand our 
mechanistic understanding of EV activities.  Much of this work has focused on the 
integral membrane proteins displayed on EV surfaces. For example, integrins laden on 
EV membranes can facilitate cell motility through interactions with extracellular matrix 
components (55).  Proteases on EV surfaces can also degrade extracellular matrix, 
contributing to lung disease (56).  In another example, dendritic cell – derived EVs 
display antigen-MHC complexes that can activate T cells (49, 50).  These critical EV 
activities do not require delivery of internal vesicle cargos. 
EV luminal cargos are also known to facilitate critical intercellular 
communications.  Indeed, the ability of EVs to delivery cargo is increasingly recognized 
for its biological importance and therapeutic potential (57).  There has been particular 
interest in the effects of EV microRNAs.  In one of the most well-documented examples, 
luminal EV microRNAs from breast cancer cells can induce non-tumorigenic cells to 
form tumors, and this activity is dependent on a component of the RNA induced 
silencing complex, strongly supporting the hypothesis that EV-delivered microRNAs 
contribute to these effects (48).  In another example, mesenchymal stem cell – derived 
EVs can ferry the anti-apoptotic microRNA-21 to surrounding heart tissues following 
ischemic injury, to prevent cell death and tissue damage (58).  Other cytoplasmic 
factors are also transmitted by EVs.  During viral infections, EVs from infected cells can 
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transmit viral genomes to naïve cells, thereby propagating infection (59).   Intriguingly, 
non-enveloped viruses, including paramyxoviruses and hepatitis A virus incorporate into 
EVs during their egress (60, 61), potentially to evade antiviral immune responses. 
Pathogenic prions and other self-aggregating proteins associated with 
neurodegenerative disease are also transferred via EVs (62, 63). These studies 
highlight just some of the biological activities mediated by internal EV cargos. 
Extracellular Vesicle Heterogeneity.   
EVs are remarkably heterogeneous.  They can range in size from 40 to over 
1000 nm in diameter, and they can contain a variety cytoplasmic and transmembrane 
cargos (64).  Their heterogeneity stems, in part, from the subcellular location of their 
biogenesis.  Some EVs, termed microvesicles, originate from budding events at the 
plasma membrane (43).  Another subset of EVs, exosomes, are instead derived from 
membrane budding into endosomes, which must subsequently fuse with the plasma 
membrane to release their luminal vesicles (44).   EVs heterogeneity also extends to the 
molecular mechanisms of their biogenesis.  Some EVs are generated by the endosomal 
sorting complex required for transfer (ESCRT) machinery (65, 66), with others are 
generated by ESCRT-independent mechanisms (67–69).  These different biogenesis 
locations and mechanisms may correlate with distinct EV structures, cargos, and 
biological functions (70–72), though these distinctions remain to be fully elucidated. 
Extracellular Vesicle Cargo Delivery and Membrane Fusion.   
EV-directed transport of cytoplasmic effectors requires several steps (Figure 4).  
First, the effectors must be incorporated into vesicles that bud out from cell-surfaces or 
endosome membranes (43, 44, 46, 47, 73, 74).  For vesicles budding into endosomes, 
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the resultant multi-vesicular bodies (MVBs) must traffic and fuse with plasma 
membranes to permit their escape as EVs (44).   Second, the secreted EVs must 
disseminate and bind to cells at nearby or distant locations (75–77).  Third, the EV 
payloads must cross the limiting EV and target cell membranes.  These EV cargo 
deliveries have been documented in cell culture (41), and recent work from Dr. Stephen 
Momma and colleagues has documented that EVs can transfer Cre recombinases to 
cell cytosols in vivo (78). 
 
Figure 4. Steps in EV Cytoplasmic Cargo Transfer.  To exclusively cytoplasmic 
molecules between cells.  First, cytoplasmic factors, including proteins (red), nucleic 
acids (blue) and small molecules (green), are loaded into EVs during their biogenesis.  
EVs then secrete by budding from the plasma membrane, or by budding into 
endosomes followed by endosome – plasma membrane fusion.  Secreted EVs 
disseminate and bind to target cells.  Finally, EVs deliver their cargo into target cell 
cytoplasms, likely through EV-cell membrane fusion. 
 
There is some evidence that EV cargo delivery can be accomplished through EV 
– target cell membrane fusion.  The first observations of EV-cell membrane fusion came 
12 
 
 
 
from Parolini and colleagues in 2009 (3).  Using EVs labeled with self-quenching 
fluorescent dyes, they documented increases in fluorescent signals after incubating 
these EVs with target cells, suggesting that quenched dyes were dispersed into target 
cell membranes by membrane fusion events.  These investigations were extended by 
Montecalvo and colleagues in 2012, who also documented the delivery of EV-
encapsulated luciferin into luciferase-expressing target cells (4).  It remains unclear, 
however, whether EVs can deliver their cargos by other mechanisms, such as 
transmembrane channels (79).  Whether EV cargo deliveries rely on EV-cell fusions 
remains a divisive question in the field (1), and factors facilitating EV-cell membrane 
fusion and cargo delivery remain to be identified.  
Cellular Membrane Fusion 
The most extensive form of membrane fusion-mediated communication is cell-
cell fusion, which facilitates the complete mixing of cell cytoplasms.  Cell-cell fusions are 
required to form many important biological structures in multicellular organisms.  For 
example, sexual reproduction depends on cell-cell fusions between gametes to 
generate fertilized zygotes (80).  During fetal development, trophoblastic cells fuse 
together to form the placenta (81).  Even after birth, cell-cell fusions continue to occur.  
Fusions between myoblasts generate long skeletal muscle fibers (82), and monocyte-
monocyte fusions generate osteoclasts that maintain skeletal integrity (83), as well as 
giant-cell macrophages that protect tissues from foreign pathogens and materials (84).   
Dysregulated cell-cell fusions are linked to disease.  Overabundant monocyte 
fusions can significantly enhance bone degradation, and contribute to both osteoporosis 
(85) and Paget’s Disease (86).  Reduced myoblast fusions have been linked with some 
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forms of muscular dystrophy (87), while inhibition of trophoblast fusions is associated 
with preeclampsia (88).  Tumor cells are also known to fuse with stromal, epithelial, and 
hematopoietic cells, and these cell-cell fusions may enhance tumor metastasis and drug 
resistance (89).  Strict control of cell-cell fusions is thus required to maintain 
homeostatic conditions in the body and prevent disease. 
Monocyte Membrane Fusion.   
Monocytes and macrophages have inherent phagocytic and degradative 
capacities, and these activities are often used to combat pathogens and remove debris 
from the body.  Under conditions where large amounts of material must be degraded or 
phagocytosed, monocytic cells fuse together to form giant multinuclear macrophages 
(GMMs) (83, 90–92).  These syncytial GMMs have a higher phagocytic and degradative 
capacities than their mononuclear counterparts, in part due to their ability to create 
large, hydrolytic extracellular compartments to mediate endocytic internalization of 
degraded materials (93). 
One form of GMMs, giant lung cell macrophages, form at sites of tuberculosis 
granulomas, and are thought to aid in degrading these large masses of material (91, 
92).  Similar GMMs also form around non-infectious foreign materials, presumably to 
facilitate their removal (90).  The monocyte fusions that generate giant lung 
macrophages can be induced by inflammatory cytokines, including IL-4 and IL-13 (84). 
Osteoclasts, another GMM, are highly specialized cells that adhere to bone and 
release degradative enzymes to resorb and remodel bone surfaces (83).  The process 
of osteoclast formation begins with the recruitment of peripheral monocytes to sites of 
skeletal repair (94, 95).  Receptor activator of NF-κB (RANK) proteins displayed on 
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these monocytes interact with RANK ligands (RANKL) on bone-depositing 
mesenchymal osteoblasts.  RANK:RANKL interactions induce monocyte differentiation 
into pre-osteoclasts (96).  During differentiation, numerous factors are upregulated, 
including tetraspanins (97), integrins (98), immunoglobulin-like proteins (99, 100), and 
seven transmembrane receptors (101).  Some of these proteins likely form complexes 
on the pre-osteoclast cell surface, and then go on to catalyze monocyte-monocyte 
fusions to form multinucleated osteoclasts (102, 103). 
Cellular Membrane Fusion Catalysts.   
While the fusion proteins of enveloped viruses are relatively well studied, it is 
surprising that eukaryotic membrane fusion catalysts have remained elusive.  Recent 
investigations, however, has made significant headway in identifying some endogenous 
membrane fusion catalysts.  Remarkably, these investigations suggest that eukaryotic 
cells have “captured” several syncytial virus fusion proteins, and have “domesticated” 
these proteins to catalyze essential membrane fusions in the absence of viral infection.   
The first bona-fide endogenous fusion catalysts discovered were two 
glycoproteins, aptly named syncytins 1 and 2, which catalyze trophoblast cell fusions 
(12, 104, 105).  These syncytins are encoded by endogenous retroviral elements that 
likely integrated into mammalian genomes during ancient retroviral infections (106).  
Syncytins retain the essential structures of viral fusion proteins (106), and likely catalyze 
membrane fusions by similar mechanisms.  In mice, each of the two expressed 
syncytins contributes to trophoblast fusion.  Disruption of both syncytins renders mice 
infertile (107), indicating the essential role these fusion proteins play in placental 
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development.  In humans, mutations in the syncytins correlate with preeclampsia, 
adding further support to this notion (88). 
 It is notable that, while syncytins are found in a wide variety of placental 
mammals, individual syncytin genes are not orthologous, and thus arose from 
independent “domestication” events (106).  It is, however, conceivable that the 
individually acquired syncytins displaced the function of a more ancient, common 
trophoblast fusogen.  Nevertheless, evolutionary studies suggest that the syncytins 
were acquired between 20 and 80 million years ago, roughly coinciding with the 
appearance of placental mammals (106).   
 While the syncytins were first thought to be exclusively expressed in 
trophoblasts, recent studies suggest that also play critical roles in the formation of 
skeletal muscle and giant cell macrophages.  Syncytin – targeting antibodies and 
peptides suppress both myoblast-myoblast and monocyte-monocyte membrane 
mergers (108, 109), suggesting that these endogenous fusion proteins may play central 
roles in many cell-cell fusion events.  The evolution of the musculoskeletal system, 
however, far preceded the acquisition of syncytin proteins, and whether syncytins are 
typically expressed in non-placental tissues is a matter of debate (12). 
 A second endogenous fusion protein, hapless 2 (HAP2), catalyzes fusion 
between gametes, and is essential for sexual reproduction in many organisms (13, 110–
112).  Unlike the syncytins, HAP2 is highly conserved across most eukaryotes, with 
orthologs expressed by some of the most evolutionarily distant eukaryotic lineages, 
suggesting that this protein was present in the last eukaryotic common ancestor (113).  
Structural modeling indicates that HAP2 proteins are highly similar to flavivirus and 
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alphavirus fusion proteins (13).  When HAP2 is disabled, gametes adhere closely 
together, but do not fuse (111), indicating this protein is essential for many gamete 
fusion events.  HAP2 is typically expressed in the “male” gamete (112), suggesting that 
human sperm may also express HAP2-like fusion proteins.  Intriguingly, however, HAP2 
has been lost in numerous eukaryotic organisms, including C. elegans, mice, and 
humans (113).  This suggests that other membrane fusion catalysts may have 
supplanted HAP2 in some eukaryotes.  Nonetheless, the conserved structures and 
origins of both endogenous and viral fusion proteins suggests that these glycoproteins 
are fine-tuned to drive membrane megers. 
Facilitators of Membrane Fusion 
In addition to activators that directly engage fusion proteins, target cells also 
contain factors that indirectly facilitate virus-cell membrane fusion.  For example, some 
lipids spontaneously generate positive membrane curvatures, likely due to the large size 
of their polar heads relative to their hydrophobic tails (9).  These lipids, including 
lysophosphatidylcholine and polyphosphoinositides, enhance membrane fusogenicity.  
Other fusion-promoting lipids, such as cholesterol and surface-exposed 
phosphatidylserines, do not directly alter membrane curvatures, but instead may control 
membrane fusion by facilitating protein-lipid and protein-protein interactions (114–116).   
Proteins can also act as indirect fusion facilitators.  In many cases, these proteins 
induce signaling pathways that likely induce the expression of membrane fusion 
catalysts and their essential cofactors (96, 101).  Integrins and adhesion proteins can 
also facilitate fusions, by holding opposing membranes in close proximity (117).  During 
cell-cell fusion, actin and its interacting partners also facilitate fusion by forming highly 
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curved cellular protrusions (118).  These protrusions subsequently interact with 
membranes reinforced by actin “sheaths” in the opposing cells (118).  Both of these 
activities likely enhance tension in cell membranes, and could thus promote membrane 
disruption and lipid mixing.  Another family of proteins, the tetraspanins, facilitate a wide 
variety of virus-cell and cell-cell fusion events, as described below.  This dissertation 
focuses on identifying and characterizing tetraspanin roles in extracellular membrane 
fusions. 
Tetraspanins 
The tetraspanins are highly conserved membrane proteins ubiquitously present 
in all eukaryotes (119).  They are composed of four (tetra) transmembrane spans 
connected by one small and one large extracellular loop (SEL and LEL, respectively) 
(Figure 5, left).  Their transmembrane domains are alpha-helical coils that interact to 
form a cone-shaped structure that tapers in the inner membrane leaflet (116).  Their 
conserved structures and activities suggest that they play a critical role in controlling 
membrane architecture and composition.  They induce positive membrane curvatures 
(120) (Figure 5, left), potentially through the cone-shaped structure formed by their 
transmembrane spans (116), which may displace lipids in the outer membrane leaflet.  
Tetrapsanins are also highly enriched in EVs (121), and facilitate EV production (122, 
123).  This activity may trace to their membrane-curving activities, as EV membranes 
acquire positive curvatures as they bud into endosomes or the extracellular space.  
Tetraspanins also interact with other integral membrane proteins and lipids, 
controlling their subcellular localization.  The tetraspanin CD81, for example, contains a 
pocket between its transmembrane domains that binds cholesterol, thereby altering LEL 
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conformations (116).  Other tetraspanins associate with palmitic acid through covalent 
interactions between this lipid and the tetraspanin cytoplasmic domains (124, 125).  In 
conjunction with these lipids, tetraspanins also interact with “partner” proteins.  
Tetraspanin transmembrane domains likely facilitate homotypic tetraspanin-tetraspanin 
interactions (126, 127), while palmitolyation facilitates hetero-typic interactions with 
other tetraspanins.  Tetraspanin LELs and cytoplasmic tails also interact with adhesion 
molecules (128), integrins (129, 130), and proteases (131), giving rise to “webs” termed 
tetraspanin-enriched microdomains (TEMs) on cell membranes (132, 133) (Figure 5, 
right).  The LELs are the most variable regions of tetraspanin proteins (133).  Individual 
tetraspanins, therefore, often have several distinct protein partners. 
 
Figure 5. Tetraspanin Structure and Protein Interactions. (Left Panel) Tetraspanins 
are composed of four transmembrane spans connected by one large extracellular loop 
(LEL) and one small extracellular loop (SEL), with short N- and C-terminal tails 
protruding into the cytosol.  They induce positive membrane curvatures in cell 
membranes, potentially due to their “cone-shaped” transmembrane domains.  (Right 
Panel) Tetraspanins (red and black) act as scaffolds for transmembrane proteins.  The 
form homo- and hetero-typic interactions with other tetraspanins through interactions 
between their transmembrane domains.  They also interact with other integral 
membrane proteins (green and yellow) through their LELs and cytoplasmic tails.  By 
interacting with multiple protein partners simultaneously, tetraspanins can “construct” 
protein complexes. 
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Tetraspanin-Enriched Microdomains.   
Early characterizations of TEMs suggest that multiple homo- and hetero-typic 
interactions between tetraspanins and their partner proteins lead to the formation of 
semi-stable membrane microdomains that are highly complex (134).  These studies 
relied on the isolation of tetraspanin-enriched membranes following detergent-mediated 
cell solubilization.  TEMs are similar to lipid rafts, but can be distinguished by their 
relative sensitivity to particular detergents (135).  Zwitterionic detergents, such as Brij99 
and CHAPs, do not disrupt membranes containing tetraspanins and TEM resident 
proteins.  It is likely that these detergents do not disrupt tetraspanin-mediated protein-
protein interactions, and also could maintain hydrophobic interactions between 
tetraspanin transmembrane domains (127).  Non-ionic detergents like Triton X-100, 
however, disrupt tetraspanin interactions, but do not disrupt canonical lipid rafts (135).  
Thus, TEM and lipid raft – resident proteins can be distinguished by isolating detergent 
resistant membranes after differential solubilization.   
These biochemical approaches, however, do not necessarily reflect the 
composition of intact TEMs found on the cell surface.  Indeed, while analysis of 
detergent resistant membranes indicates that heterotypic tetraspanin-tetraspanin 
interactions occur (134, 136), high-resolution stimulated emission depletion microscopy 
indicates that most TEMs form from homotypic tetraspanin-tetraspanin interactions, with 
TEMs containing approximately 3-4 tetraspanins (137).  Therefore, while dynamic 
heterotypic tetraspanin-tetraspanin interactions may have important biological activities, 
these heterotypic interactions may be more transient that initially thought. 
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Tetraspanins in Virus Entry.   
Accumulating evidence indicates that TEMs act as platforms for virus entry.  The 
strongest evidence for this is in the context of hepatitis C virus (HCV) entry (138).  Here, 
the tetraspanin CD81 acts as a direct receptor for the HCV E2 membrane fusion 
protein.  In other cases, tetraspanins and TEM resident proteins likely promote entry 
without directly engaging viral fusion proteins.  These viruses include human 
cytomegalovirus (HCMV) (139), lujo virus (140), human papilloma virus (HPV) (141), 
influenza A virus (IAV) (28, 142), and several alphaviruses (143, 144).  For example, the 
tetraspanin CD151 coalesces receptor-bound HPVs and their integrin co-receptors.  
These co-receptors contain endocytic motifs, and thus these CD151-mediated 
interactions facilitate virus endocytosis (141, 145).  In addition, while CD81 binds 
directing to the HCV E2 fusion protein, it also coalesces the HCV co-receptors 
syndecan-1, scavenger receptor B1, and claudin-1 into a complex that drives HCV 
endocytosis (146, 147).  Intriguingly, there is evidence that the MERS-CoV receptor 
DPP4 binds the tetraspanin CD9 (148), suggesting that MERS-S receptor binding, and 
subsequent proteolytic priming, may also take place in TEMs.  Overall, these data 
suggest that many viruses have evolved to utilize closely interacting entry factors on 
target cells, and that tetraspanins aggregate these factors into TEMs. 
Tetraspanins in Non-Viral Membrane Fusion.   
Outside of viral infection, tetraspanins and TEMs control a wide variety of 
important endogenous biological activities, including cell metabolism and signal 
transductions.  They are also known to play critical roles in cellular membrane fusion 
events.  During cell-cell fusion, tetraspanins may form complexes with other proteins 
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essential for these membrane fusion processes (102, 103), and they are often found on 
the tips of cellular protrusions where cell-cell membrane mergers are thought to occur 
(149).  The evidence that tetraspanins facilitate cell-cell fusion is most striking in the 
context of fertilization, where CD9 is absolutely required for gamete fusion.  During 
gamete fusion, CD9 can be found on the tips of oocyte cellular extensions (149).  Here, 
CD9 plays a critical role in maintaining these extensions, potentially through their 
membrane-curving properties.  CD9 knockout mice are infertile, with oocytes lacking 
CD9 are entirely unable to fuse with adhered sperm cells (150).  Intriguingly, CD9-
containing EVs can compensate for this loss of CD9 by linking sperm and egg cells and 
subsequently catalyzing their fusion in a process known as “fusion-from-without” (151).  
Tetraspanins also control myoblast and monocyte fusion events.  CD9 overexpression 
facilitates osteoclast formation (97), and CD9 is an integral component of the 
multiprotein complexes that likely drive monocyte membrane mergers (83).  CD9-
targeting antibodies also suppress the fusion of myoblasts (152), suggesting that the 
tetraspanin protein family may generally regulate cell-cell fusion events. 
Inhibitors of Membrane Fusion 
Cells do not just rely on membrane fusion facilitators to tightly control membrane 
fusion processes.  They also rely on fusion inhibitors to restrict membrane fusion 
potential.  The roles of fusion-inhibiting lipids have been relatively well studied.  For 
example, the lipids phosphatidylethanolamine and diacylglycerol contain relatively bulky 
hydrophobic tails and small hydrophilic head groups.  These lipids therefore 
spontaneously generate negative membrane curvatures that suppress interactions 
between opposing membranes and decrease membrane fusogenicity (9).  In addition, 
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cells can also express fusion-inhibiting proteins.  B cell – produced antibodies can 
engage virus fusion proteins to “neutralize” their fusion potential (153).  In addition, cells 
can express interferon-induced transmembrane (IFITM) proteins, which act to inhibit 
enveloped virus membrane fusion.  Below, we will discuss the IFITM protein family in 
more detail. 
Interferon-Induced Transmembrane Proteins 
IFITM proteins are type II transmembrane proteins approximately 130 residues in 
length (154).  They are constituents of the larger dispanin protein family, members of 
which are found across all domains of life (155).  Dispanins are composed of two 
alphahelical domains within the cell membrane linked by an intracellular loop.  In the 
case of the IFITMs, the first of these alphahelical domains is amphipathic (156), and 
intercalates into the inner leaflet of the lipid bilayer (157).  It is connected to a long 
cytosolic N-terminal tail.  The second domain spans the entire bilayer to expose a short 
C-terminal tail into the extracellular space (154) (Figure 6, Front View).  Phenylalanine 
residues in the first membrane span facilitate homo- and hetero-typic IFITM 
mutimerization (158).  The human genome contains five ifitm genes.  Some ifitms, 
ifitm1, 2, and 3, are expressed abundantly in response to type 1 interferons (159, 160).  
These interferon-induced IFITMs have been most extensively studied, particularly in the 
context of enveloped virus infection.   
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Figure 6. Structure of the IFITMs. (Front View) IFITMs are short type II 
transmembrane proteins with two alphahelical transmembrane domains.  A relatively 
long N-terminal tail precedes the first helix.  This helix is amphipathic, and intercalates 
into the inner leaflet of the lipid bilayer.  The second helix is truly transmembrane, and 
exposes a short C-terminal tail to the extracellular space.   (Side View) By intercalating 
into the inner leaflet of the lipid bilayer, the amphipathic helix may displace lipids, 
thereby generative negative membrane curvatures.  This could be why the amphipathic 
helix is absolutely required for IFITM antiviral activities.  
 
IFITM Activities during Enveloped Virus Entry.   
During viral infection, viral gene products induce the production of type I 
interferons, which upon secretion and subsequent receptor binding induce the 
expression of hundreds of antiviral interferon-stimulated genes (ISGs), including the 
IFITMs (161).  Once elevated, IFITM family members 1, 2 and 3 line the limiting 
membranes of the cell to restrict enveloped virus entry, preventing fusion between viral 
and host cell membranes (162–164).  When endogenously expressed, the localization 
of each IFITM is tightly regulated, with IFITM1 present at the cell surface, IFITM2 in 
early endosomes, and IFITM3 in late endosomes and lysosomes (164, 165).  The 
susceptibility of enveloped viruses to individual IFITMs is therefore dictated by the 
subcellular sites of virus-cell membrane fusions (165).  In addition, IFITMs can 
incorporate into the membranes of budding enveloped viruses, reducing their fusion 
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potential in a process termed “negative-imprinting” (166, 167).  Virus-incorporated 
IFITMs appear to be more suppressive than IFITMs in target cell membranes (166), 
possibly because viruses-incorporated IFITMs cannot be bypassed by alternative entry 
routes.  In addition to being present on cell membranes and viruses, notably IFITMs 
also incorporate into EVs during viral infections (168).  IFITM-containing EVs bind to 
cells, reducing their permissiveness to viral infection by unclear mechanisms. 
While mechanisms of IFITM-mediated fusion inhibition are not fully elucidated, it 
is known that the first alphahelical domain is essential for its antiviral activities.  This 
domain consists of an amphipathic helix that intercalates into the inner leaflet of the lipid 
bilayer (156), and may induce fusion-inhibiting negative membrane curvatures (Figure 
6, Side View).  In addition, there is some evidence that IFITMs reduce membrane 
fluidity (169), which could restrict membrane fusogenicity.  IFITM multimerization is also 
critical for fusion inhibition (158), potentially because such interactions aid in 
concentrating IFITMs on cell membranes.   
While alternative explanations involving speculative IFITM-induced, fusion-
inhibitory cell signaling pathways have not been entirely ruled out, the current literature 
suggests that IFITMs act locally at sites of virus-cell membrane fusion to block 
membrane mergers.  Local IFITM activities may involve interactions with the platforms 
that catalyze membrane fusions.  IFITMs are post-translationally palmitoylated, which 
facilitates their incorporation into TEMs (170, 171).  There, they can alter or displace 
contacts between tetraspanins and their partner proteins.  For example, IFITM5 disrupts 
interactions between the tetraspanin CD9 and CD81 (136).  In addition, IFITM1 
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dysregulates HCV co-receptor interactions, and this correlates with inhibition of HCV-
cell membrane fusion (172). 
Non-Viral IFITM Activities.   
In the absence of viral infection, IFITM family members are also linked to a 
diverse array of biological activities, including cell fate and development, tumor 
malignancy, and maintenance of bone morphology (136, 173–177).  The importance of 
IFITMs outside of viral infection is exemplified in the autosomal – dominant severe 
brittle bone disease Osteogenesis Imperfecta (OI) type V, which is caused by 
polymorphisms in the ifitm5 locus (178–180).  OI type V patients have fragile bones that 
are prone to fracture, even in the absence of trauma (180, 181).  IFITM5 is expressed in 
the skeletal system (177), as well as in some immune cells, including monocytes (182).  
In bone-depositing, mesenchymal osteoblasts, it is known to suppress bone 
mineralization, which intriguingly correlates with the ability of IFITM5 to disrupt CD9 and 
CD81 interactions (136).  While interferon-induced IFITMs control membrane fusion, 
IFITM5 is not responsive to interferons, and whether this proteins has diverged 
functionally is unclear.  Given the homology of IFITM5 to its interferon-induced 
counterparts (183, 184) however, it is possible that this protein acts to control 
membrane fusions in the skeletal system, such as monocyte cell-cell fusions. 
Elucidating the molecular mechanism of OI type V is critical, as canonical treatments 
are ineffective against this form of OI, and may even exacerbate disease (185).   
Two mutations in IFITM5 are known to cause OI.  One mutation, (c.-14C > T), 
generates a new translational start site that adds five residues (MALEP) to the N-
terminus of the protein (178, 179).  Murine models of MALEP-IFITM5 – induced OI 
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indicate that this mutation significantly disrupts fetal skeletal development and leads to 
perinatal lethality (186).  Expression of MALEP-IFITM5 in bone-depositing osteoblasts 
decreases bone mineralization and collagen secretion (186–188), suggesting that this 
mutant disrupts bone deposition.  MALEP-IFITM5 patients, however, also accumulate 
large bone deposits that are not resorbed, particularly at sites of fracture, suggesting 
that bone formation is not simply reduced, but also dysregulated.  A second mutation, 
(c.119C > T), generates a serine to leucine mutation in the predicted second 
transmembrane span of the protein (IFITM5(S40L)) (180).  IFITM5(S40L) also leads to 
OI, but symptoms appear distinct from the MALEP-IFITM5 mutation.  Rather than 
accumulating large deposits of bone, patients harboring IFITM5(S40L) have thin bones 
with no observable deposits.  Increased bone resorption in these patients suggests that 
bone-resorbing osteoclasts may contribute to disease.  Overall, these phenotypes 
suggest that IFITM5 plays a central role in controlling skeletal maintenance, and also 
suggest that the two identified IFITM5 mutations may cause distinct forms of disease 
(189).   
Purpose of Dissertation 
A review of the literature suggests that tetraspanins and TEMs may act generally 
to regulate extracellular membrane fusion events.  However, the mechanisms by which 
TEMs control these fusion events have not been fully explored. We aimed to further 
understand extracellular membrane fusions by focusing on these potential fusion 
platforms.  We hypothesized that TEMs are platforms for virus, EV and cell membrane 
fusions, and that TEM composition regulates these fusion events.  We tested these 
hypotheses using three distinct experimental systems.   
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The first system evaluated virus-cell fusions, using MERS-CoV as a model.  The 
tetraspanins clearly promote interactions between the cofactors that many enveloped 
viruses use to fuse with cells in culture (141, 146, 147).  However, it is unclear whether 
TEMs are critical for viral infections in vivo, and their roles during CoV entry remain 
unexplored.  We predicted that tetraspanins and TEMs would control CoV membrane 
fusions both in cell culture and in vivo. 
The second system evaluated vesicle – cell fusions, using EVs as a model.  EVs 
ferry their luminal contents between cells, but whether membrane fusions facilitate EV 
cargo deliveries is contentious.  In addition, while tetraspanins and IFITMs incorporate 
into EVs (121, 168), potential mechanisms of EV-cell fusion remain unexplored, and it is 
unknown whether they control EV cargo transfer.  We speculated that EV-cell fusions 
drive cargo deliveries and intercellular communications, and that tetraspanins and TEM 
resident proteins regulate these fusion events. 
The third system evaluated cell – cell fusions, using monocytes as a model.  We 
hypothesized that IFITM5 restricts monocyte cells fusions, and that restriction is 
dysregulated by disease – causing IFITM5 mutations.  Given the ability of IFITM5 to 
disrupt CD9 and CD81 interactions (136), we also speculated that IFITM5 may act 
through tetraspanins to exert these effects. 
In all experimental systems, we monitored the transfer of cargos between cells, 
to gain insights into the membrane platforms regulating vesicle – cell, virus – cell, and 
cell – cell fusion events. Our results identify tetraspanins and TEM resident proteins as 
central components in a striking variety of membrane fusion processes, illustrating how 
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membrane dynamics in diverse environments are controlled by a limited set of common 
elements. 
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CHAPTER TWO 
MATERIALS AND METHODS 
Cells and Reagents 
293T, HeLa, and murine mesenchymal stem cells (MSCs) were maintained in 
Dulbecco's Modified Eagle Media (DMEM) supplemented with 10% fetal bovine serum 
(FBS, Atlanta Biologicals), 10 mM HEPES, 100 mM sodium pyruvate, 0.1 mM non-
essential amino acids,100 U/ml penicillin G, and 100 μg/ml streptomycin (HyClone).  
Mouse astrocytoma DBT cells were maintained in MEM-7.5 (minimal essential medium 
[MEM] supplemented with 7.5% FBS, 10% tryptose phosphate broth [Difco], 100 IU/ml 
penicillin, 1 mg/ml streptomycin, and 2 mM L-glutamine).  Murine macrophage 
RAW264.7 cells were maintained in Minimum Essential Alpha Medium (α-MEM) (Life 
Technologies) supplemented with 10% fetal bovine serum (FBS) (Atlanta Biologicals) 
and 1% penicillin-streptomycin solution (Thermo Scientific). Cells were maintained in a 
humidified environment at 37oC and 5% CO2.   
Polyclonal rabbit antibodies directed against GFP were obtained from Katherine 
Knight (Loyola University Chicago).  Monoclonal mouse antibodies against CD9 (clone 
M-L13), CD63 (clone H5C6), and CD81 (clone JS-81) were obtained from BD 
Pharmingen.  Mouse anti-KDEL antibodies were obtained from Stressgen Bioreagents.  
Polyclonal rabbit IFITM3 antisera (ab74699) were obtained from Abcam.  Rabbit anti-
FLAG antibodies were obtained from Sigma Aldrich. Hoechst 33258, goat-anti-mouse-
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AlexaFluor 647, goat-anti-rabbit-AlexaFluor 488, goat-anti-mouse-AlexaFluor 488 
and goat-anti-rabbit-AlexaFluor 568 antibodies were purchased from Invitrogen.  
AlexaFluor 647-conjugated wheat germ agglutinin was obtained from Molecular Probes. 
Actin was detected with anti-β-actin peroxidase (Sigma).  Goat anti-mouse and goat 
anti-rabbit HRP conjugated antibodies were purchased from Thermo Scientific.  Murine 
recombinant IFN-β was purchased from R&D Systems. 50 mM Amphotericin B (Fischer 
Scientific) stock solutions were prepared in DMSO.  Murine sRANKL was obtained from 
Peprotech.  
Plasmids and Cloning 
Codon-optimized MERS-CoV S containing a C9 tag was purchased from 
Genscript and subsequently cloned into pcDNA3.1+ between the EcoRI and NotI 
restriction sites. C-terminal Flag-tagged human DPP4 (hDPP4) plasmid pCMV6-Entry-
hDPP4 (catalog no. RC209466) (CMV stands for cytomegalovirus) was purchased from 
OriGene. pLVX-CD63 was kindly provided by Adarsh Dharan (Loyola University 
Chicago). Rluc8155-156DSP(1-7) and Rluc8155-156DSP(8-11) were kindly provided by 
Zene Matsuda (University of Tokyo).  pEGFP-C1 was a gift from Chris Wiethoff (Loyola 
University Chicago).  psPax2 was a gift from Didier Trono (Addgene plasmid #12260).  
pLentiCRISPR v2 was a gift from Feng Zhang (Addgene plasmid #52961)(190). To 
generate membrane tethered DSPs, sequences encoding the N-terminal 15 residues of 
c-Src (sequence: 
ATGGGGAGCAGCAAGAGCAAGCCCAAGGACCCCAGCCAGCGCCGG) were 
introduced at the 5’ ends of DSP genes.  The DSPs were subsequently cloned into 
pCAGGs-MCS (191) between ClaI and NheI restriction sites.  S15-mCherry was 
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previously constructed (192).  The pHEF-VSV-G plasmid was obtained from BEI 
Resources.  pCMVSport6-hCD9 was purchased from Open Biosystems and 
subsequently cloned into pLVX between EcoRI and ApaI restriction sites.  The CD81 
ORF was cloned from pEE6-CD81 into pLVX between EcoRI and ApaI restriction sites. 
pCMV-Sport6-hIFITM3 was purchased from open Biosystems and subsequently cloned 
into pCAGGS between SacI and XhoI restriction sites. The pCAGGS vector encoding 
for the spike (S) fusion protein of murine hepatitis virus (MHV) strain A59 (pCAGGS-
MHV-A59S) was previously constructed (193), as was  pCAGGS-TMPRSS2-FLAG (34).  
The cognate receptor of MHV-A59S, CEACAM, was cloned into pcDNA3.1(+) between 
HindIII and XhoI restriction sites. pLVX and ΔNRF were kindly provided by Edward 
Campbell, Loyola University Chicago.  Human natural and MALEP-IFITM5 were 
purchased from GenScript.  A C-terminal Flag tag was added to both IFITM5s during 
subsequent cloning into pLVX between XhoI and EcoRI restriction sites, generating 
pLVX-IFITM5-FLAG and pLVX-MALEP-IFITM5-FLAG.  pLVX-IFITM5(S40L)-FLAG was 
generated using NEBuilder HiFi DNA Assembly Cloning Kit (New England BioLabs), 
template pLVX-IFITM5-FLAG and the following primers: forward, 5’– 
ACCACTTGATCTGGTTGGTGTTCAGCACCC – 3’; reverse  5’ – 
GGGTGCTGAACACCAACCAGATCAAGTGGT – 3’; forward, 5’ – 
CCTGTGTGAAATTGTTATCCGCTCAC – 3’; reverse, 5’ – 
GTGAGCGGATAACAATTTCACACAGG – 3’.  
Transfections 
Plasmid DNA transfections were performed with polyethylenimine (PEI; 
Polysciences) at a ratio of 1 μg DNA:3 μg PEI. All DNAs were transfected into cells at a 
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concentration of 0.5 μg / million cells.DNA/PEI complexes were incubated in Opti-MEM 
(Life Technologies) for 20 min at room temperature before they were added dropwise to 
adherent cells. 18 h post-transfection, cells were rinsed with PBS and incubated in cell 
culture media.  293T cell transfection efficiencies were measured using pEGFP-C1.  
Transfection conditions typically resulted in >90% EGFP+ cells.   
Generation of CD9 Knockout Cells 
pSpCas9-BB-2A-puro was digested with Esp3I (Fermentas) for 4h at 37°C. The 
digested plasmid was purified and ligated with annealed guide DNAs specific for CD9 or 
CD81. Tetraspanin-specific pSpCas9-BB-2A-puro plasmids were transfected into 293T 
cells. After 72h, cells were selected with 4 μg/ml puromycin for 96h. Selected cells were 
serially-diluted to isolate clonal populations and clones were selected by western blot. 
Pseudoviruses 
HIV pseudoviruses were produced as previously described [84]. Briefly, 293T 
cells were co-transfected with pNL4.3-HIV-luc and pcDNAs encoding appropriate 
glycoproteins. After two days, supernatants were collected, centrifuged at 10,000 x g at 
4°C for 10 minutes to remove debris, and stored in aliquots at -80°C. VSV 
pseudoviruses were produced by the methods of Whitt, 2010 [40]. Briefly, 293T cells 
were transfected with plasmids encoding viral glycoproteins. Two days later, cells were 
inoculated for 2h with VSVΔG-luciferase, rinsed extensively and incubated for one day. 
Supernatants were collected, centrifuged at 10,000 x g at 4°C for 10 minutes to remove 
cellular debris, and stored in aliquots at -80°C. 
Pseudovirus transductions were carried out by incubating target cells with 
pseudoviruses for 1h at 37°C. Following initial incubation, unadsorbed viruses were 
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removed by washing thrice with PBS. Complete media was placed on the cells and 
incubated for 18h for VSV or 48h for HIV at 37°C. At the end of transduction periods, 
cells were dissolved into cell culture lysis buffer (25 mM Tris-phosphate [pH 7.8], 2 mM 
DTT, 2 mM 1,2-diaminocyclohexane-N,N,N ′,N ′-tetraacetic acid, 10% glycerol, 1% 
Triton X-100) and luciferase levels were measured by addition of firefly luciferase 
substrate (1 mM D-luciferin, 3 mM ATP, 15 mM MgSO4·H2O, 30 mM HEPES [pH 7.8]) 
using a Veritas microplate luminometer (Turner BioSystems, Sunnyvale, CA). 
Isolation of Tetraspanin-Enriched Membranes  
Adherent 293β5 cells (~105 / cm2 ) were rinsed with ice-cold PBS, incubated for 
30 min at 4o C with 1 mg / ml EZ-Link Sulfo-NHS-LC-Biotin (Pierce) in PBS, rinsed, 
then incubated for 20 min at 4o C with 100 mM glycine in PBS. Cells were rinsed with 
PBS, then incubated for 20 min at 4o C in MES buffer (25 mM MES [pH 6.0], 125 mM 
NaCl, 1 mM CaCl2, 1 mM MgCl2) containing 1% 3-[(3- Cholamidopropyl) 
dimethylammonio]-1-propanesulfonate (CHAPS) detergent (Calbiochem Cat # 220201) 
or 1% TritonX-100 detergent (Sigma). Cell lysates (107 / ml) were removed from plates 
and emulsified by 20 cycles of extrusion through 27G needles. Nuclei were removed by 
centrifugation, lysates mixed with equal volumes of 80% w/v sucrose in MES buffer, 
placed into Beckman SW60 tubes, and overlaid with 3 ml of 30% w/v sucrose, then with 
0.5 ml of 5% w/v sucrose, both in MES buffer. Samples were centrifuged with a 
Beckman SW60 rotor at 370 K x g for 18 h at 4o C. Fractions were collected from air-
gradient interfaces. Biotinylated proteins in gradient fractions were bound to streptavidin 
agarose beads (Pierce). Non-reducing dot- and western-blotting procedures were used 
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to identify the distributions of proteins in gradient fractions, as described previously 
[162]. 
Recombinant Adenovirus Production 
Recombinant adenovirus vectors were produced by the University of Iowa Gene 
Transfer Vector Core. To generate TMPRSS2-expressing adenoviruses, hTMPRSS2 
containing a C-terminal FLAG tag was cloned into the pAd5CMV shuttle vector between 
XhoI and EcoRI restriction sites. To generate shRNA—expressing adenoviruses, gene 
blocks containing an shRNA targeting either the coding region of CD9 (target sequence: 
CCGATTCGACTCTCAGACCAA) or the 3' UTR of TMPRSS2 (target sequence: 
ACACTAGAGTGGATGAATGTCTGGA), flanked by the U6 promoter and RNApolIII 
termination sequence, were purchased from GenScript. These gene blocks were 
subcloned into the pacAd5k-NpA E1 shuttle vector between the KpnI and EcoRI 
restriction sites. Shuttle vectors were linearized and transfected into HEK 293 cells 
along with a linearized Ad5 backbone containing an RSV promoter -driven hDPP4 in the 
E3 region. Homologous recombination in HEK 293 cells yielded recombinant 
adenovirus encoding both the shRNA and hDPP4. Titers of purified recombinant 
adenoviruses ranged from 1010−1011 pfu/ml. 
Transduction and Infection of Mice 
Isoflurane-anesthetized mice were transduced intranasally with 2.5 x 108 pfu of 
the indicated Ad5 virus in 75 μl of DMEM. 5 days posttransduction, mice were infected 
intranasally with 105pfu of MERS-CoV in a total volume of 50 μl DMEM. At 2 d.p.i., mice 
were euthanized by isoflurate inhalation followed by cervical dislocation. Lungs were 
removed into PBS and manually homogenized. Virus was plaqued on Vero81 cells. 
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Cells were fixed with 10% formaldehyde and stained with crystal violet 3 d.p.i. All work 
was performed in the University of Iowa Biosafety Level 3 (BSL3) Laboratory.  
EV Isolation 
EV producer cells were co-transfected with the indicated DNAs by PEI transfection.  
24-36h post-transfection, cells were incubated with serum free DMEM (1mL / million cells) 
for 12 h at 37°C.  Where indicated, 100nM Bafilomycin A1 (Sigma-Aldrich) or DMSO 
vehicle control were added to media before application to cells. Conditioned media were 
subjected to sequential centrifugation at 300xg for 10 min, 2000xg for 10 min, and 
10,000xg for 30 min to remove cells, cell debris, and apoptotic bodies, respectively, to 
leave EVs in the 10,000xg supernatants.  For microscopic analyses, EVs were collected 
in serum-free DMEM lacking phenol red.   
Transmission Electron Microscopy 
EVs were pelleted by ultracentrifugation and resuspended in PBS containing 2% 
PFA and processed by the methods of Thery, 2006 (194).  Briefly, EVs were deposited 
onto Formvar-carbon coated EM grids and allowed to adsorb for 20 min.  Grids were 
rinsed once in PBS, fixed in 1% glutaraldehyde for 5 min, and subsequently rinsed 8 
times in distilled water.  Fixed EVs were then contrasted using uranyl-oxalate for 5 min, 
and embedded in 2% methyl cellulose containing 4% uranyl acetate for 10 min on ice.  
Excess methyl cellulose was removed and grids allowed to air dry.  Grids were 
subsequently observed using a Philips CM120 Transmission Electron Microscope.  
Western Blot Analyses 
EVs in 10,000xg supernatants were subjected to ultracentrifugation under 
conditions that pellet all particles with sedimentation coefficients >100 S.  Where 
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indicated, sodium dodecyl sulfate (SDS) was added to 10,000xg supernatants to a final 
concentration of 0.1% prior to ultracentrifugation.  Pelleted vesicles were rinsed by 
resuspending in PBS and re-pelleting by ultracentrifugation.  EVs and cells were 
dissolved on ice for 15 min with TX-100 buffer (1% Triton X-100, 25 mM Tris-HCl [pH 
7.4], 125 mM NaCl, 0.1% protease inhibitors, 1 mM MgCl2, 1 mM CaCl2) and debris 
removed by centrifugation at 1000xg for 10 min at 4°C.  The TX-100 extracts were then 
mixed with 1/6th volume of 6x SDS buffer (0.375 M Tris HCl [pH 6.8], 10% SDS, 6% 2-
mercaptoethanol, 30% glycerol) and heated to 95°C for 5 min.  When probing for 
tetraspanin proteins, 2-mercaptoethanol was not added to SDS buffer. A total of 50,000 
cell equivalents, in parallel with the indicated cell equivalents of EV lysates, were 
subjected to sodium dodecyl sulfate - polyacrylamide gel electrophoresis (SDS-PAGE).  
Separated proteins were transferred to nitrocellulose membranes (BioRad), the 
membranes incubated in Tris-buffered saline with tween (20mM Tris-HCL, 150mM 
NaCl, 0.1% Tween-20 [pH 7.6]) (TBST) containing 5% milk for 1 hour at room 
temperature, and subsequently incubated with the appropriate primary antibodies at a 
1:1000 dilution in TBST-1% milk for 1 hour at room temperature.  Membranes were then 
rinsed thrice in TBST, incubated with the appropriate secondary antibodies at a 1:5000 
dilution in TBST-1% milk.  Finally membranes were rinsed, treated with ECL substrate 
(Pierce), and detected with FluorChem E and analyzed with Alphaview software 
(Protein Simple). 
Quantifying EV Concentration 
293T cells were transfected with either DSP8 or S15-DSP8, along with 
TMPRSS2, CD9, CD63, CD81, or a vector control.  24-36 h post-transfection, EVs were 
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collected during a 12 h of incubation period in serum free DMEM, in the presence or 
absence of 100 nM bafilomycin A1.  After media were clarified, EVs were observed by 
nanoparticle tracking analysis using a NanoSight LM10-HS (Malvern Instruments) at the 
Keck Biophysics Facility (Northwestern University), or using a NanoSight 300 (Malvern 
Instruments) at Capricor Therapeutics (Beverly Hills, CA).  3 samples were analyzed to 
determine vesicle concentration and size distribution for each condition. Videos were 
processed identically post-acquisition. 
Quantifying EV Cargo Secretion by Luciferase Assay 
293T-DSP1/8 cells were modified through addition of S15-tethers to the DSPs, or 
through co-transfection with TMPRSS2, CD63, CD9, or CD81. 24-36 h post-
transfection, EVs were collected from the cells over a 12 h period with or without 
bafilomycin A1.  EV-containing media were mixed with 1/5th volume of 5x Passive Lysis 
Buffer, EV producer cells lysed in 1x Passive Lysis Buffer, and luminescence measured 
by addition of Renilla luciferase substrate, and quantified as RLU using a Veritas 
microplate luminometer. Rluc RLU in EV-containing media and producer cells were 
compared to quantify the proportion of total Rluc in the media. 
Quantifying Intercellular Transfer of DSPs  
293T-DSP1, DBT-DSP1 or MSC-DSP1 cells were inoculated with conditioned media 
from corresponding DSP8 cells.  After 2 h, DSP1 cells were rinsed once in PBS, lysed 
in Passive Lysis Buffer, and luminescence was measured by addition of Renilla 
luciferase substrate, and quantified as RLU using a Veritas microplate luminometer.  
Modification of DSP8 cells was required to yield detectable DSP8 transfers into DSP1 
cells.  To yield detectable DSP8 transfers, unless otherwise indicated, 293T EV 
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“producer” cells were routinely co-transfected with pCAGGS-hTMPRSS2-FLAG 
andRluc8155-156DSP(8-11). In some experiments, as indicated, EV-containing media 
were normalized to Rluc RLU content as described above.  Also where indicated, DSP8 
EVs were pre-bound to cells as described above. 
Monitoring Intercellular Transfer of DSPs by Fluorescence Microscopy 
EV-containing media were isolated from 293T cells transfected with S15DSP8 
and VSVG.  After removing cells and cellular debris by centrifugation, these EV 
containing media were then incubated with 293T-S15DSP1 cells for 2 hours at 37°C.  
Cells were then rinsed thrice in PBS and fixed for 30 minutes at 37oC with 3.7% 
paraformaldehyde (PFA) in 0.1 M piperazine-N,N′-bis(2-ethanesulfonic acid) [pH 6.8] 
(PIPES) buffer.  Cells were blocked for 1 hour in PBS containing 2% FBS, and 
subsequently stained with AlexaFluor 647-conjugated wheat-germ agglutinin (Molecular 
Probes) and Hoescht for 20 minutes to label cell surface lectins and nuclei, respectively.  
Cells were then rinsed and mounted onto slides. Images were captured using a 
DeltaVision microscope (Applied Precision) equipped with a digital camera (CoolSNAP 
HQ; Photometrics), using a 1.4-numerical aperture 60X objective lens.  Images were 
deconvoluted with SoftWoRx deconvolution software (Applied Precision).  Deconvolved 
imaged were analyzed for transferred and complemented DSPs (GFP+ puncta) 
usingthe Spots Mode of the Imaris 6.3.1 software package (Bitplane Scientific 
Solutions). Algorithms were designed that detected local fluorescent signals with a 
quality above background fluorescence.  
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Analysis of EV-Cell Binding 
24-36 h post-transfection, EVs were collected in serum free media over 12 h from 
293T-DSP1/8 cells transfected with the indicated proteins.  A portion of the supernatant 
was mixed with 1/5th volume of 5x Passive Lysis buffer (Promega), and luminescence 
measured by addition of Renilla luciferase substrate and quantified as RLU using a 
Veritas microplate luminometer.  Serum free DMEM was then used to normalize Rluc 
levels in supernatants across all conditions.  Normalized EV-containing media were 
then bound to 200,000 target cells plated in 24 well plates, at a multiplicity of 150 RLUs 
per cell, for 2 h, using 13°C to prevent EV internalization and cargo delivery.  Cells were 
then rinsed once in PBS, lysed in 1x Passive Lysis Buffer, and luminescence was 
measured by addition of Renilla luciferase substrate, and quantified as RLU using a 
Veritas microplate luminometer.  The percent of Rluc-containing EVs bound to cells was 
inferred by comparing Rluc RLU signals on cells to those in media. 
Production of IFITM3 KO Cells 
To generate IFITM3 – targeting CRISPR-Cas9 lentiviral vectors, the pLentiCRISPRv2 
plasmid was digested with BsmB1 for 30 min at 37°C.  Oligonucleotides containing 
guide DNA targeting IFITM3 (target sequence: CTGCCAGTGGAGGACAGCCC) were 
subsequently ligated into the digested plasmid.  To produce CRISPR-Cas9 – containing 
pseudoviruses to knockout IFITM3, 293T cells were transfected withpHEF-VSV G, 
psPax2, and the IFITM3 – targeting pLentiCRISPRv2.  2 days post-transfection, 
pseudovirus – containing media were collected and centrifuged at 1000xg for 10 min to 
remove cell debris.  Pseudoviruses were then used to transduce DBT cells.  2 days 
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post-transduction, DBT cells were selected with puromycin (4 µg/mL) for 2 weeks.  
IFITM3 knockout was confirmed by Western blot analysis. 
Quantifying IFNβ – Mediated Blockade of EV Cargo Transfer 
Serum free DMEM containing the indicated doses of murine recombinant IFN-β (R&D 
Systems) were applied to WT or IFITM3 KO DBT-DSP8 cells that had been co-
transfected with TMPRSS2 at 24-36 h post-transfection.  12 h later, conditioned media 
were collected, clarified, and applied to corresponding WT or IFITM3 KO DBT-DSP1 
cells.  2 h later, media were removed, cells rinsed in PBS, and lysed in Passive Lysis 
Buffer.  Luminescence in target cells was then measured by addition of Renilla 
luciferase substrate and quantified as RLU using a Veritas microplate luminometer. 
In Vitro EV-Virus and EV-EV Fusion Assays 
Pseudoviruses for EV-virus fusion assays were generated by co-transfecting 293T cells 
with HEV-VSV G, psPax2, and S15-DSP8.  EVs for EV-virus fusion assays were 
generated by transfecting 293T cells with either S15-DSP8, and by co-transfecting 
separate 293T cells with S15-DSP1, S15-mCherry, and IFITM3 or vector control.   24-
36 h post-transfection, all cells were incubated with serum free, phenol red – free 
DMEM for 12 h at 37°C.  Conditioned media were then collected and clarified.  EVs 
containing S15-DSP1 and mCherry, with or without IFITM3, were then mixed with S15-
DSP8 – containing EVs, or pseudoviruses.  Mixed virus and EV containing media were 
subsequently incubated for 4h at 37°.  In the context of virus-EV fusion, media pH was 
then adjusted to 5.2 and incubated for 30 min at 37°C before being subsequently 
neutralized to pH 7.2. EVs were chilled to 4oC and centrifuged onto coverslipsat 
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2,000xg for 2 h, fixed with 3.7% PFA in 0.1 M PIPES buffer, mounted onto coverslips, 
and observed by fluorescence microscopy. 
Fluorescence Microscopic Analyses of EVs 
EVs on coverslips were permeabilized in PBS containing 0.2% Triton-X 100 for 5 min, 
exposed to PBS containing 2% FBS for 1 h, and subsequently incubated withrabbit anti-
IFITM3, mouse anti-CD9 or mouse anti-CD63 antibodies, at a 1:500 dilution, in PBS 
containing 2% FCS for 1 hour at room temperature.  Coverslips were then rinsed, 
incubated with secondary antibodies, at a 1:1000 dilution, in PBS containing 2% FCA 
for 1 hour at room temperature, mounted onto slides using PermaFluor Mountant, and 
observed by fluorescence microscopy.  Images were captured using a DeltaVision 
microscope (Applied Precision) equipped with a digital camera (CoolSNAP HQ; 
Photometrics), using a 1.4-numerical aperture 60X objective lens.  Images were 
deconvoluted with SoftWoRx deconvolution software (Applied Precision).  Deconvolved 
imaged were analyzed for EV puncta usingthe Spots Mode of the Imaris 6.3.1 software 
package (Bitplane Scientific Solutions).  Co-localizations between IFITM3+ and CD63+, 
CD9+, or mCherry+ puncta were also analyzed using the Spots Mode of the Imaris 
software package.  Algorithms were designed for each experiment that detected local 
fluorescent signals with a quality above background fluorescence.  Algorithms were 
applied to each image in the data set, and puncta enumerated using Batch.  For co-
localization, the fluorescent intensity of the other signal of interest within each spot was 
used to assess co-localization. 
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Production of ifitm5 – Encoding Lentiviral Particles and Stable Cell Lines 
10 cm dishes of 293T cells were transfected with 2.7 µg of ΔNRF, 2.7 µg pHEF-VSV-G, 
and 2.7 µg of pLVX containing CD9, the appropriate IFITM, or vector control using PEI 
transfection.  48 hours after transfection, virus-containing supernatants were harvested 
and centrifuged at 1,000 x g at 4oC for 10 minutes to clear them of cellular debris.  The 
cleared supernatants were aliquoted and stored at -80oC until use.  RAW264.7 cells 
were transduced with the appropriate retroviral vector, and after 4 days cells were 
selected with 2 μg/mL puromycin. 
Immunofluoresence Microscopy of RAW Cells 
RAW264.7 cells transduced with retroviral vectors encoding for IFITM5-FLAG, MALEP-
IFITM5-FLAG, or IFITM5(S40L)-FLAG were rinsed with PBS and fixed with 3.7% 
paraformaldehyde in 100 mM piperazine-N,N′-bis(2-ethanesulfonic acid) (PIPES) buffer 
(pH 6.8). When appropriate, cells were then permeabilized in PBS containing 0.2% 
Triton-X 100 for 5 minutes at RT.  Cells were then rinsed and incubated in PBS 
containing 2% FBS for 1 hour at room temperature (RT).  Antibodies were added, and 
cells were incubated for 1 hour at RT.  Cells were rinsed with PBS, and Alexa Fluor-
conjugated secondary antibodies were applied for 1 hour at RT, along with fluorescently 
labeled wheat germ agglutinin and Hoechst 33258 (Molecular Probes). Cells were 
mounted using PermaFluor Mountant (Thermo Scientific), and imaged with a 
DeltaVision microscope (Applied Precision) equipped with a digital camera (CoolSNAP 
HQ; Photometrics).  Images were deconvolved with SoftWoRx deconvolution software 
(Applied Precision). Colocalization was measured and quantified using Imaris version 
6.3.1 (Bitplane Scientific Solutions). 
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Osteoclast Formation Assay 
RAW264.7 cells expressing the indicated IFITM or vector control were plated on 
coverslips at a density of 5000 cells/cm2 and stimulated with 50 ng/mL sRANKL.  When 
appropriate, cells were inoculated with 250 ng/mL amphotericin B or DMSO control 24 
hours post sRANKL stimulation.  5 days after sRANKL stimulation, cells were rinsed in 
PBS and fixed with 3.7% p-formaldehyde in 100 mM PIPES buffer.  
Immunofluorescence microscopy was performed as indicated above.  The percent of 
total nuclei in multinucleated cells was then quantified from 1000 cells, counted in at 
least 20 different fields for each experiment, from three experiments. 
Osteoclast Differentiation Assay 
RAW264.7 cells expressing the indicated IFITM or a vector control were plated at a 
density of 5000 cells/cm2 and stimulated with 50 ng/mL sRANKL.  5 days later, cells 
were fixed with 3.7% p-formaldehyde in 100 mM PIPES buffer and stained for tartrate – 
resistant acid phosphatase with the Acid Phosphatase, Leukocyte (TRAP) kit (Sigma-
Aldrich) according to manufacturer's instructions. Microscopy was performed on a Leica 
DM IRB microscope (Leica Microsystems) using a MagnaFire 2.1C digital camera 
system (Optronics).  Images were processed using ImageJ (National Institutes of 
Health). 
Viral Syncytia Formation Assay 
RAW264.7 cells expressing the appropriate IFITM were infected with GFP – expressing 
Murine Hepatitis Virus strain A59.  2 hours post – infection, inoculum was removed and 
cells were incubated in the presence of 250 ng/mL amphotericin B or DMSO control for 
44 
 
 
 
16 hours. Cells were then rinsed in PBS and fixed with 3.7% p-formaldehyde in 100 mM 
PIPES buffer.  Immunofluorescence microscopy was performed on a Leica DM IRB 
microscope (Leica Microsystems) using a MagnaFire 2.1C digital camera system 
(Optronics).  The percent of GFP+ nuclei in multinucleated cells was quantified from 500 
cells in three experiments. 
Statistical Analysis 
Statistical comparisons were made by two-tailed Student’s t-test.  Data are represented, 
unless otherwise noted, as means ± SEM. 
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CHAPTER THREE 
RESULTS 
SECTION 1: TEMs as Platforms for Virus-Cell Membrane Fusion 
The Tetraspanin CD9 Facilitates MERS-CoV Entry. 
Given the roles of tetraspanins in the entry of many enveloped viruses, as 
discussed in Chapter 1, we speculated that they would also control CoV entry, 
potentially at the level of membrane fusion.  Since the MERS-CoV receptor DPP4 binds 
the tetraspanin CD9 (148), we sought to determine whether this tetraspanin played a 
role in MERS-CoV entry.  To this end, we used CRISPR/Cas9 technologies (195) to 
eliminate CD9, or alternatively the tetraspanin CD81, from 293T cells.  Western blot 
analyses of cell lysates confirmed CD9 and CD81 knockout (KO), while the expression 
of the tetraspanin CD63 was unaffected in both cell lines (Figure 7A).  
Immunofluorescence analysis (IFA) of unpermeabilized cells confirmed that the KO cells 
were depleted of the appropriate tetraspanin (Figure 7B).  To determine whether 
293TKO cells were resistant to MERS-CoV entry, we utilized MERS-S – laden HIV-
based pseudoparticle (pp) transductions, which allowed us to limit our readouts to virus-
cell entry events.  We rendered 293T “wild type” (WT) and KO cells permissive to 
MERS-CoV transductions by transfecting them with DPP4, and subsequently 
transduced them with MERSpps.  Notably, CD9KO restricted MERSpp transductions by 
over 1 log (Figure 7C).  Ectopic expression of CD9 rescued MERSpp entry in these  
46 
 
 
 
cells.  The requirement for CD9 was MERS-specific, as SARSpp transductions were not 
inhibited in CD9KO cells when its ACE2 receptor was ectopically expressed (Figure 
7D).  CD81KO did not significantly inhibit entry of MERS- or SARSpps, though there 
was a modest decrease in SARSpp entry that was eliminated when CD81 was 
ectopically expressed (Figure 7E-F).  These results indicated that CD9, but not CD81, is 
a MERS-CoV entry factor.  They also suggested that all CoVs do not rely on the same 
tetraspanin to facilitate viral entry. 
 
 
Figure 7. CoV Entry into Tetraspanin KO Cells. (A) Western blot analysis of 293T 
and HeLa clonal cell lines. Actin and the tetraspanin CD63 are used as loading controls. 
(B) Immunofluorescent analysis of HeLa clonal cell lines. Unpermeabilized cells were 
incubated with primary antibodies against CD9, CD81 or CD63 as indicated. 293T WT, 
CD9KO (C-D), or CD81KO (E-F) cells were transfected with the appropriate receptors 
and CD9 where indicated. These cells were transduced with viruses pseudotyped with 
S proteins from MERS (C and E) or SARS (D and F).  Pseudovirus transduction was 
measured by luciferase assay. Experiments performed with the aid of James Earnest. 
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CD9 Holds DPP4 in TEMs. 
 Given the ability of tetraspanins to aggregate proteins into TEMs (133), we 
predicted that CD9 functioned to localize DPP4 to these membrane microdomains.  If 
so, DPP4 would localize to membranes resistant to solubilization by CHAPS detergent 
(135).  Thus, we ectopically expressed the MERS receptor DPP4, the SARS receptor 
ACE2 (196), or the CoV-triggering protease transmembrane protease serine 2 
(TMPRSS2) in WT and KO cells, and subjected the cells to surface-biotinylation.  Cells 
were then lysed in CHAPS detergent to dissolve cell membranes without destroying 
TEM protein-protein interactions.  Lysates were then fractionated along a sucrose 
gradient.  After fractionation, CHAPS-soluble proteins were in the high-density (HD) 
fractions at the bottom of the gradient, while CHAPS-insoluble protein-lipid complexes 
were in the low-density (LD) fractions at the top of the gradient.  Cell surface proteins in 
these fractions were subsequently precipitated using streptavidin, and fractions were 
then probed for CoV receptors and proteases by Western blot.  Notably, DPP4 was 
present in LD membrane fractions only when CD9 was expressed (Figure 8A), while 
CD81KO had no effect on DPP4 localization.  Localization of ACE2 and TMPRSS2, 
however, were unaffected by CD9 or CD81 KO (Figure 8B-C).  These results suggested 
that CD9 specifically interacts with DPP4 to hold it in TEMs. 
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Figure 8. Association of CoV Entry Factors with CHAPS-resistant Membranes in 
the Presence or Absence of CD9 or CD81. 293T WT, CD9KO, or CD81KO cells were 
transfected with the CoV receptors DPP4 (A), ACE2 (B), or the protease TMPRSS2 (C). 
KO cells were also complemented with the appropriate tetraspanin. Cell-surface 
proteins were biotinylated before cells were lysed in cold CHAPS and cleared lysates 
were subjected to ultracentrifugation. Cell surface proteins were isolated by streptavidin 
pulldown and analyzed in high density (HD) and low density (LD) fractions by western 
blot.  Experiment performed by James Earnest. 
 
CD9 Brings DPP4 and TMPRSS2 into Close Proximity. 
 Our evaluations of CHAPS-resistant membrane fractions suggest that CD9 holds 
DPP4 receptors in TEMs, which also contain the CoV-triggering protease TMPRSS2 
(Figure 8).  Given that MERS-S receptor binding is required for productive triggering 
(24), we questioned whether CD9 held DPP4 and TMPRSS2 closely together to 
facilitate virus entry.  We thus determined whether DPP4 and TMPRSS2 were in close 
proximity on cell surfaces, and whether CD9 facilitated these close interactions.  We did 
this using proximity ligation assays (PLAs) (197), which can determine whether 
transmembrane proteins are within 40 nm of each other (198).  Antibodies tagged with 
oligonucleotide probes are bound to cells, and close spacing between probes facilitates 
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oligonucleotide hybridization into templates for DNA polymerase, thereby providing 
substrates for fluorescent DNA synthesis. 
 CD9KO HeLa cells, which have relatively flat morphologies suitable for PLAs, 
were incubated with DPP4 and TMPRSS2 antibodies, and after incubation with 
secondary antibodies tagged with PLA probes and subsequent DNA amplification, 
fluorescent DNAs were detected by immunofluorescence assay (IFA).  Notably, close 
interactions between DPP4 and TMPRSS2 were rarely observed in CD9KO cells 
(Figure 9A), while CD9 ectopic expression increased detectable interactions by ~10 fold 
(Figure 9D).  When DPP4 or TMPRSS2 were overexpressed, they closely interacted 
even in the absence of CD9 (Figure 9B, C, E).  Interactions were most prevalent when 
all three proteins were ectopically expressed (Figure 9F).  The number of detectable 
PLA foci per cell correlated with cell susceptibility to viral transduction (Figure 9G-H).  
These data suggest that CD9 facilitates MERS-CoV entry by linking DPP4 and 
TMPRSS2 on the cell surface.  They also suggest that CD9-mediated linkages are 
especially important when DPP4 and TMPRSS2 levels are low. 
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Figure 9. Proximity Ligation Assay of DPP4 and TMPRSS2 in CD9KO Cells. (A-F) 
HeLa CD9KO cells were transfected with the indicated genes and a GFP reporter 
before being mounted on microscopy slides. Proximity ligation assay was performed 
using primary antibodies against hDPP4 and hTMPRSS2. Red foci indicate close 
proximity of the two proteins. (G) The average number of foci/cell in GFP+ cells in each 
group was quantified. (H) MERSpp transduction of HeLa cells overexpressing the 
indicated proteins.  Experiment performed by James Earnest. 
 
CD9 and TMPRSS2 Are Critical for MERS-CoV Infection in vivo. 
As shown in Figure 9, CD9 links DPP4 with TMPRSS2 on the cell surface of 
cultured cells.  These data also suggest that CD9-mediated linkages are critical for 
TMPRSS2-triggered MERS-CoV early entry.  However, whether these factors are 
required for MERS-CoV lung infection was unknown. To identify host factors critical for 
MERS-CoV entry in vivo, we developed dual-expressing adenoviral serotype 5 (Ad5) 
vectors encoding for the MERS-CoV receptor human DPP4 (hDPP4), along with either 
TMRPSS2 or shRNAs targeting CD9 or TMPRSS2 mRNAs.  In this system, only Ad5-
transduced cells are susceptible to MERS-CoV infection, as ectopic expression of 
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human (h)DPP4 is required for MERS-CoV entry into mouse cells (199).  Therefore, all 
cells permissive to viral infection are also depleted of candidate entry factors.   
To confirm the Ad5-expressed shRNAs depleted their target genes, mouse LET-
1 cells were transduced with Ad5 vectors, and cells were subsequently lysed and 
probed for DPP4, CD9, and TMPRSS2 by Western blot or RTqPCR.  These assays 
confirmed that the Ad5 vectors overexpressed and depleted their target proteins in LET-
1 cells (Figure 10 A-B).  As expected, DPP4-expressing Ad5 vectors rendered cells 
permissive to MERSpp entry, and TMPRSS2 overexpression enhanced entry into these 
cells (Figure 10C).  Conversely, TMPRSS2 and CD9 depletion rendered cells less 
permissive to MERSpps.  These data indicated that CD9 and TMPRSS2 are critical 
entry factors in LET-1 cells, and that Ad5-expressed gene products modulated the 
expression of these factors. 
 To determine whether CD9 and TMPRSS2 are required for MERS-CoV entry in 
vivo, our colleague Dr. Kun Li at the University of Iowa transduced mice intranasally 
with Ad5 vectors, and after 5 days challenged with MERS-CoVs.  2 days post-infection, 
lungs were harvested and MERS-CoV titers quantified by plaque assay on Vero cells.  
Notably, depletion of either TMPRSS2 or CD9 reduced MERS-CoV titers by ~10 fold 
and ~20 fold, respectively (Figure 10D).  TMPRSS2 overexpression, however, did not 
enhance MERS-CoV titers, presumably due to high endogenous expression of serine 
proteases in the mouse lung.  These data indicate that, remarkably, MERS-CoV lung 
infections are largely driven by a single tetraspanin, and a single protease.  These 
results also suggested that MERS-CoVs utilize cell surface, rather than endosomal, 
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factors to enter mouse lung cells. 
 
Figure 10. Analysis of Adenovirus Knockdown of MERS-CoV Entry Factors in Cell 
Culture and in vivo. (A) LET-1 cells were transduced with an adenovirus carrying a 
GFP gene or adenoviruses carrying hDPP4 and either an empty vector, the TMPRSS2 
gene, or a U6-driven shRNA against TMPRSS2 or CD9. After 3 days, cells were lysed 
and analyzed by western blot for the indicated proteins. (B) Quantitative rtPCR analysis 
of Tmprss2 transcripts in cells transduced with rAd5-hDPP4-EV and rAd5-hDPP4-
shTmprss2. (C) LET-1 cells were transduced with the indicated Ad5 vector before 
transducing with VSV-MERSpp. Transduction was measured by luciferase assay. (D) 
The indicated Ad5-DPP4 vectors were installed intranasally in C57/Bl6 mice. 5 days 
later, mice were infected with MERS-CoV. Lungs were isolated at 2 dpi and viral titers 
were measured by plaque assay. Experiments performed with the assistance of James 
Earnest and Kun Li. 
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SECTION 2: TEMs as Platforms for Extracellular Vesicle Membrane Fusions 
Membrane Fusion Drives EV Content Transfer. 
EV-mediated cargo transfers facilitate critical intercellular communications, 
however, the molecular mechanisms of EV cargo delivery are unknown.  This is, in part, 
due to the lack of simple quantitative assays to monitor EV-cell cytoplasmic exchange.  
To develop an approach to measure EV cargo transfer, we looked to technologies 
developed by Dr. Zene Matsuda and colleagues to monitor cell-cell fusion and 
cytoplasmic exchange (200).  These technologies rely on the EV-mediated transfer of 
Dual-Split Renilla luciferase (Rluc): Green Fluorescent Protein (GFP) Protein (DSP) 
fragments to target cells expressing the complementary DSP fragments.  Upon delivery 
into the cell cytosol, EV-ferried fragments will complement with target cell DSP 
fragments to form active Rluc and GFP reporters (Figure 11).  This approach provides 
rapid readouts of cytoplasmic exchange that are readily quantified; therefore, we sought 
to utilize these DSP fragments to monitor EV-cell fusion and cytoplasmic exchange.   
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Figure 11. Diagram of EV Cargo Transfer Assay Using the DSP Reporter System.  
DSP8 (green and blue) is incorporated into EVs in 293T producer cells and secreted.  
Released DSP8 – containing EVs bind to DSP1 expressing target cells, where 
subsequent EV cargo deliveries mediate DSP complementation and reporter gene 
expressions (yellow).  
To facilitate DSP incorporation into EV lumens, we noted that membrane 
tethered proteins are preferentially loaded into EVs (201), and thus tethered the DSPs 
to lipid bilayers by appending an acylated membrane anchor, S15 
(MGSSKSKPKDPSQRR) (192, 202).  First, to determine whether EVs carried DSP 
cargo, EV-containing media were collected from 293T-S15DSP8 cells and subsequently 
cleared of cell, cell debris, and apoptotic bodies by differential centrifugation. EVs were 
then pelleted by ultracentrifugation.  EVs could be observed in the pelleted material by 
transmission electron microscopy, and displayed cup-like morphologies consistent with 
the literature (Figure 12A) (194).  Pellets also contained DSP8 cargo, along with the 
tetraspanins CD63 and CD9 (Figure 12B), which are enriched in EV membranes (64).  
Pre-incubating media with sodium dodecyl sulfate (SDS) prevented these proteins from 
being pelleted, suggesting they were contained in membranous EVs.   
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To determine whether the S15 tether enhanced DSP8 loading into EVs, we 
ectopically expressed both S15-DSP8 and S15-DSP1 in cells, thereby rendering those 
cells Rluc+.  Rluc levels in EV-containing media harvested from DSP1/8 or 
S15DSP1/S15DSP8 cells were then measured to quantify DSP cargo release.  Many 
EVs are under 200 nm in diameter, the limit of detection by light microscopy.  We 
therefore relied on nanoparticle tracking analysis (NTA), which allows one to observe 
small particles through light-scattering (203), to enumerate vesicles in conditioned 
media.  The results indicated that S15-tethers did enhance EV cargo loading by over 50 
fold (Figure 12C, red data points), while only modestly increasing EV output (Figure 
12C, blue data points).  These results indicated that S15-tethering facilitated DSP 
loading into EVs.  However, inoculation of S15-DSP8+ EVs onto S15-DSP1 target cells 
did not generate luciferase or fluorescent signals. 
We hypothesized that EVs did not deliver S15-DSP8 cargos because they were 
unable to fuse with target cells.  To address this concern, we ectopically expressed the 
fusion glycoprotein of vesicular stomatitis virus (VSVG) in EV producer cells.  Notably, 
this fusion protein rendered EVs transfer competent (Figure 12D), with luciferase 
signals indicative of cargo deliveries appearing within 2 hours of incubation at 37°C.  
Intracellular GFP puncta could also be observed in some inoculated cells (Figure 12E), 
providing additional evidence that DSPs were successfully transferred in the presence 
of a bona-fide virus fusion protein.  These findings indicate that membrane fusion 
catalysts can drive EV cargo delivery, and suggest that 293T cell EVs have relatively 
poor membrane fusion potential. 
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Figure 12. Membrane Fusion Drives EV Cargo Transfers. (A) Transmission electron 
microscopy image of EVs harvested from 293T-S15DSP8 producer cells.  Scale bar = 
50 nm. (B) Conditioned media from EV-producing cells were incubated with or without 
0.1% SDS.  EV particles were then pelleted by ultracentrifugation and the EV-
associated proteins were subjected to Western immunoblotting to detect DSP8, CD63, 
CD9 and β-actin. (C) EVs from 293T-DSP1/8 and 293T-S15DSP1/S15DSP8 cells were 
collected over a 12-h period.   Rluc RLU associated with EV-containing media and 
producer cells were measured and plotted as the proportion of total Rluc in the media 
(red data points).  Data bars represent means ± SEM. In parallel, EVs were collected 
from conditioned 293T-DSP8 cells and particle concentrations were quantified by 
nanoparticle tracking analysis (blue data points).  Data bars represent means ± SD. (D) 
EV-containing media were collected from 293T-S15DSP8 cells overexpressing the 
fusion protein VSVG or a vector control.  EVs were then inoculated onto 293T-DSP1 
target cells.  After 2h at 37oC, DSP8 cargo delivery was measured by its 
complementation with DSP1 into Rluc RLU.  Data bars represent means ± SEM. 
*p<0.05, compared to control DSP1-containing EV transfers onto DSP1 target cells. (E) 
DSP complementations in cells incubated with VSVG-laden EVs as in (D) were 
identified by intracellular GFP+ puncta (white arrows).  Wheat-germ agglutinin (red) and 
Hoescht (blue) labeled cell-surface lectins and nuclei, respectively.   
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Tetraspanins Promote EV Release and Enable Cargo Transfer. 
Although cells can express virus-like fusion catalysts (12, 13), their expression 
does not appear universal (12, 113), and therefore many EV cargo transfers are likely 
enabled by other factors.  Intriguingly, tetraspanin overexpression increases EV 
secretion (122, 123).  Tetraspanins also interact with adhesive proteins (128), and CD9-
positive EVs drive fusion-incompetent gametes to fuse through “fusion-from-without” 
(151).  Due to these known tetraspanin activities, we hypothesized that tetraspanin 
overexpression would enable EV cargo transfers.  Indeed, ectopic expression of CD9, 
CD63, or CD81 in EV producer cells permitted EV cargo transfers, with target cell 
complementation signals readily observed after 2 h of incubation with EV-containing 
media (Figure 13).  Notably, tetraspanins functioned exclusively in EV producer cells to 
promote EV cargo transfer, as they were inert when expressed in EV target cells.   
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Figure 13. Tetraspanins Act in Producer Cells to Enable EV Cargo Transfers. EV-
containing media were collected from 293T-DSP8 cells overexpressing the indicated 
tetraspanins or a vector control.  EVs were then inoculated onto 293T-DSP1 target 
cells.  After 2h at 37oC, DSP8 cargo delivery was measured by its complementation with 
DSP1 into Rluc RLU.  Data bars represent means ± SEM. *p<0.05, compared to control 
DSP1-containing EV transfers onto DSP1 target cells. 
 
Tetraspanins could conceivably promote EV cargo transfers by enhancing EV 
output, EV-target cell binding, or EV-cell membrane fusion. To determine whether 
tetraspanins acted at the level of EV cargo loading or release, we ectopically expressed 
tetraspanins in Rluc+ 293T-DSP1/8 cells and quantified Rluc levels in EVs.  
Nanoparticle tracking analysis was again used to enumerate vesicles in conditioned 
media. The results indicated that tetraspanins did enhance both EV outputs (Figure 
14A, blue data points) and EV cargo release (Figure 14A, red data points).  These 
results were confirmed by Western blot, which indicated that EVs from tetraspanin 
overexpressing cells were enriched in both DSP and tetraspanin cargos (Figure 14C).  
EV outputs, however, did not correlate with cargo transfer readouts (Figure 14B).  For 
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example, CD9 was the most potent facilitator of EV output, the least potent facilitator of 
EV cargo deliveries.  These results suggested that tetraspanins also act at the EV-
target cell binding or fusion stages during cargo transfer.   
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Figure 14. Tetraspanins Promote EV Secretion and Cargo Transfer.  (A) In the 
same experiments as Figure 12C, 293T-DSP1/8 cells were transfected with the 
indicated tetraspanins or a vector control.  EVs were then collected from the cells over a 
12-h period.   Rluc RLU associated with EV-containing media and producer cells were 
measured and plotted as the proportion of total Rluc in the media (red data points).  
Data bars represent means ± SEM. In parallel, EVs were collected from conditioned 
293T-DSP8 cells and particle concentrations were quantified by nanoparticle tracking 
analysis (blue data points).  Data bars represent means ± SD. (B) EVs collected from 
conditioned 293T-DSP8 cells were inoculated onto 293T-DSP1 target cells.  After 2h at 
37oC, DSP8 cargo delivery was measured by its complementation with DSP1 into Rluc 
RLU.  Data bars represent means ± SEM. (C) EVs were isolated from tetraspanin-
overexpressing cells by ultracentrifugation. Select proteins in the EV-producing 293T-
DSP8 cells and the secreted EVs were detected by Western immunoblotting. 
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Tetraspanins Act at the Level of EV Cargo Delivery to Enable EV Transfers.  
To determine whether tetraspanins facilitate EV-target cell binding, Rluc levels in 
EV preps were used to normalize DSP cargo loads across all conditions.  After 
normalization, EVs were then bound to target cells at equivalent input multiplicities for 2 
h at 13°C, to prevent endocytosis.  Unbound EVs were then removed, cells lysed, and 
bound EV levels quantified with a luminometer.  Less than 1% of EVs bound to target 
cells under these conditions, with tetraspanins having no effect on EV-cell binding 
(Figure 15A).  To determine whether tetraspanins drove EV cargo deliveries, 293T-
DSP1 cells with bound DSP8+ EVs were incubated at 37°C to allow bound EVs to fuse 
and deliver their cargo into target cell cytosols.  Remarkably, tetraspanin-enriched EVs 
delivered DSP8 into target cells, while EVs with basal tetrapanin levels did not (Figure 
15B).  These results indicated that tetraspanins enabled EV cargo delivery at some 
stage post-binding, likely at the level of membrane fusion.  They also suggested that 
EVs vary in their transfer competency, with tetraspanin-enriched EVs comprising a 
fusion-competent EV population. 
62 
 
 
 
 
Figure 15. Tetraspanins Drive EV Content Delivery into Target Cells. (A) EV-cell 
binding: DSP1/8 (Rluc-positive) EVs were incubated with 293T target cells at equivalent 
input multiplicities (150 RLUs/cell) for 2h at 13°C.  Unbound EVs were removed with a 
PBS rinse cycle and the remaining cell-associated EVs quantified by Rluc RLU 
measurements.  Data bars represent means ± SEM.  (B) EV cargo delivery: DSP8-
containing (Rluc-negative) EVs were bound to 293T-DSP1 target cells, and unbound 
EVs were removed, as described in (A).  Cells were then replenished with EV-free 
media and incubated for 2h at 37oC.  DSP8 cargo deliveries into target cells were 
quantified by Rluc RLU measurements.   The percentage of cell-bound EVs that 
delivered their DSP8 cargoes were inferred from the binding data in (A). Data bars 
represent means ± SEM. 
 
Additional Enablers of EV-mediated Cargo Transfer. 
In addition to tetraspanins, several other conditions promote EV release, 
including ATP (204), calcium ionophores (205), ER stress agents (206), bafilomycin A1 
(baf) (207), and proteases (208).  However, it was unclear whether the EVs produced 
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under these conditions could deliver their cargo into target cells.  We therefore treated 
Rluc+ 293T-DSP1/8 cells with baf, or overexpressed TMPRSS2.  As expected, these 
conditions facilitated the release of both EVs (Figure 16A, blue data points) and DSP1/8 
cargo (Figure 16A, red data points).  These results were confirmed by Western blotting 
of EV and cell lysates (Figure 16B).  Notably, applying these conditions to 293T-DSP8 
cells also endowed EVs with cargo transfer capacity (Figure 16C).  Applying the same 
conditions to EV target cells, however, did not facilitate cargo transfer (Figure 16D).  
These data indicate that a wide variety of EV producer cell modifications can endow 
EVs with transfer competency, and that these factors act specifically in EV producer 
cells. 
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Figure 16. TMPRSS2 and Baf Enhance EV Outputs and Enable EV Content 
Transfer. (A) In the same experiments as Figure 12C, 293T-DSP1/8 cells were 
transfected with the protease TMPRSS2 or treated with bafilomycin.  EVs were then 
collected from the cells over a 12-h period.   Rluc RLU associated with EV-containing 
media and producer cells were measured and plotted as the proportion of total Rluc in 
the media (red data points).  Data bars represent means ± SEM. In parallel, EVs were 
collected from conditioned 293T-DSP8 cells and particle concentrations were quantified 
by nanoparticle tracking analysis (blue data points).  Data bars represent means ± SD. 
(B) EVs were isolated from modified producer cells by ultracentrifugation Select proteins 
in the EV-producing 293T-DSP8 cells and the secreted EVs were detected by Western 
immunoblotting. (C) EVs collected from modified 293T-DSP8 cells were inoculated onto 
293T-DSP1 target cells.  After 2h at 37oC, DSP8 cargo delivery was measured by its 
complementation with DSP1 into Rluc RLU.  Data bars represent means ± SEM. (D) 
EVs collected from 293T-DSP8 cells were inoculated onto modified 293T-DSP1 target 
cells.  After 2h at 37oC, DSP8 cargo delivery was measured by its complementation with 
DSP1 into Rluc RLU.  Data bars represent means ± SEM. 
 
Type I Interferons Block EV Cargo Transfer through IFITM3. 
 While VSVG and tetraspanins were sufficient to enable EV cargo transfers, it was 
still unclear whether membrane fusions were required for EV cargo delivery. To 
determine whether membrane fusions are required for EV cargo delivery, we looked for 
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similarities between EVs and enveloped viruses.  We turned to type I interferons (IFNs), 
which suppress multiple stages of viral replication, including virus-cell fusion (161).  To 
determine whether IFNs block EV cargo transfer, we performed transfer assays in DBT 
cells, which are more responsive to IFN than 293T cells.  TMPRSS2-expressing DBT-
DSP8 cells produced EVs that could transfer cargo into DBT-DSP1 cells (Figure 17A), 
and these transfers were inhibited by IFN-β in a dose dependent manner.  IFN-β did not 
reduce DSP expression or EV output, as determined by Western blot (Figure 17B), 
indicating that inhibition was not at the level of EV production. 
 While over 500 IFN-induced genes (ISGs) exist, only one families of ISGs, the 
IFITM proteins, are known to generally block virus-cell fusion (162, 164).  We thus 
hypothesized that IFNs suppressed cargo transfer through IFITM3, the only murine 
IFITM that is interferon-induced (209).  We generated IFITM3 knockout (KO) DBT cells 
using CRISPR-Cas – expressing lentiviral vectors, and performed EV cargo transfers in 
the presence of IFN-β.  Notably, IFITM3 KO rescued EV cargo transfer in the presence 
of IFN (Figure 17C-D), indicating that IFN acted through IFITM3 to block EV cargo 
transfer. 
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Figure 17. IFN Inhibits EV-directed Cargo Transfer through IFITM3. (A) EV-
producing DBT-DSP8 cells were incubated with increasing doses of IFN-β for 12 h, then 
EVs were harvested and inoculated onto DBT-DSP1 target cells.  After 2h at 37oC, 
DSP8 cargo transfer was measured by its complementation with DSP1 into Rluc RLU. 
Data bars represent means ± SEM, (n=3).  (B)  Selected proteins in DBT-DSP8 
producer cells and secreted EVs were detected by Western immunoblotting.  IFITM3 
was observed as an IFN-β induced product.  (C)  EV-producing WT and IFITM3 KO 
DBT-DSP8 cells were incubated with IFN-β for 12 h.  EVs harvested from the IFN-β 
treated WT and IFITM3 KO cells were inoculated onto parallel WT and IFITM3 KO DBT-
DSP1 target cells.   After 2h at 37oC, complementation was detected by measuring Rluc 
RLU.  Data bars represent means ± SEM, (n=3).  (D) Selected proteins in WT and 
IFITM3 KO DBT-DSP8 producer cells were detected by Western immunoblotting.  
 
IFITM3 Blocks EV Cargo Transfer at the Level of Membrane Fusion. 
 IFITMs can block virus-cell membrane fusion by lining the limiting membranes of 
target cells (162, 164), or by incorporating into viral envelopes (166, 167).  We 
hypothesized that IFITMs functioned similarly to block EV-cell membrane fusion.  It was 
therefore possible that IFITM3 acted in either EV producer or target cells to block cargo 
transfer.  To identify the sites of EV transfer blockade, IFITM3 was expressed in either 
EV producer or target cells.  When expressed in producer cells, IFITM3 incorporated 
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into EVs (Figure 18B), but did not block the secretion of EVs (Figure 18A), EV-
associated tetraspanins (Figure 18B), or DSP8, indicating that IFITM3 acted after EV 
biogenesis.  IFITM3-containing EVs also bound to target cells at levels equivalent to 
IFITM3-negative EVs (Figure 18C), but were unable to deliver their DSP cargos into 
target cell cytosols (Figure 18D).  It is noteworthy that IFITM3 also blocked EV cargo 
transfer when expressed in target cells (Figure 18D), but IFITM3 was far more effective 
when present in EVs.  These data indicated that IFITM3 acted to block EV cargo 
delivery after target cell binding.  
68 
 
 
 
 
Figure 18. IFITM3 Inhibits EV-directed Cargo Transfer.  (A) EVs were harvested 
from IFITM3(-) or (+) 293T-DSP8 cells and particle concentrations were quantified by 
nanoparticle tracking analysis.  Data bars represent means ± SEM. (B) EVs were 
harvested from IFITM3(-) or (+) 293T-DSP8 cells and pelleted by ultracentrifugation.  
Selected proteins in pelleted EVs and in producer cell lysates were detected by Western 
immunoblotting. (C) EVs were harvested from IFITM3(-) or (+) 293T-DSP1/8 producer 
cells and absorbed onto 293T target cells at equivalent input multiplicities (250 
RLUs/cell) for 2 h at 13°C.  Media were removed, cells rinsed once in PBS, and the 
percentage of cell-bound EVs were quantified by Rluc RLU measurements.  Data 
represent means ± SEM.  (D) EVs were harvested from IFITM3(-) or (+) 293T-DSP8 
producer cells.  The EVs were inoculated onto IFITM3(-) or (+) 293T-DSP1 target cells, 
as indicated under the graphical data.  After 2 h at 37oC, DSP8 cargo delivery was 
measured by its complementation with DSP1 into Rluc RLU. Data bars represent 
means ± SEM. 
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To directly determine whether IFITM3 blocks EV-cell membrane fusions, we 
noted that vesicle-vesicle fusions can occur in conditioned media (210).  We expected 
these vesicle-vesicle fusions could be registered at the single vesicle level by DSP 
complementations, and that IFITM3 would block these fusion events.  Thus, EVs 
containing S15-mcherry and DSP8, with or without IFITM3, were co-incubated with HIV-
based, VSVG-laden pps containing DSP1 (Figure 19A).  VSVpp-EV fusions were 
readily observed after 30 min of incubation at pH 5.2, and these fusions were inhibited 
by over a log in the presence of IFITM3 (Figure 19B).  Surprisingly, EV-EV fusions were 
also observed after 4 hours of incubation at 37°C (Figure 19C), and these fusions were 
also blocked by IFITM3.  These data indicated that IFITM3 blocks EV-EV membrane 
fusions, and strongly suggest that IFITM3 acts similarly to block EV-cell fusion and 
cargo transfer. 
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Figure 19. IFITM3 Inhibits in vitro EV-virus and EV-EV Fusions. (A) Diagram of in vitro 
fusion assay. EVs contained DSP8 and were without (-) or with (+) IFITM3.  EVs also contained 
the red fluorescent EV marker S15-mCherry.  EVs were then mixed with DSP1-containing EVs 
or VSVG pps (A) or not (B).  GFP puncta resulting from these co-incubations reflect vesicle-
vesicle fusion events. (B) EVs were mixed with DSP1-containing VSV pseudoviruses under 
acidic (pH 5.0) conditions for 30 min at 37oC, to trigger VSV G protein-mediated fusion catalysis.  
(C) EVs were mixed with DSP1-containing EVs under neutral (pH 7.0) conditions for 4 h at 
37oC.  After mixing, the vesicles were pelleted onto coverslips and analyzed by fluorescent 
microscopy.  Green GFP+ punctae (products of EV-virus and EV-EV fusion) were quantified 
relative to the more abundant mCherry+ punctae representing unfused vesicles.  Data bars 
represent means ± SEM. Experiment performed by Enya Qing.  
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IFITM3 Preferentially Incorporates into Tetraspanin-containing EVs. 
 Given that EV-incorporated IFITM3 blocked 85-90% of DSP transfers and EV-EV 
fusions (Figures 18-19), we speculated that IFITM3 was present in the majority of EVs.  
Immunofluorescence analysis of EVs from IFITM3 and S15-mCherry expressing 
producer cells, however, indicated that IFITM3 was actually present in only ~20% of all 
EVs (Figure 20A).  To explain this discordance, we noted that IFITMs interact with 
tetraspanins, and hypothesized that IFITM3 preferentially incorporated into tetraspanin-
enriched EVs.  Indeed, IFITM3 incorporated into ~40% of S15-mCherry EVs containing 
CD9 or CD63, while only ~15% tetraspanin-negative S15-mCherry EVs contained 
IFITM3 (Figure 20B-C).  These data indicate that IFITM3 preferentially incorporates into 
tetraspanin-enriched, transfer-competent EVs. 
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Figure 20. IFITM3 Incorporates into a Subset of Tetraspanin – containing EVs. (A) 
EVs were harvested from 293T-mCherry cells that were without (-) or with (+) IFITM3.  
EVs were fixed, permeabilized, and stained for IFITM3 (green).  The percent of mCherry 
(red) EVs harboring IFITM3 was quantified using Imaris Software. Data represent 
means ± SEM, (n=3). Scale bar = 10 µm.  (B) EVs harvested from 293T-mCherry-
IFITM3 cells were fixed, permeabilized, and stained for CD9 (blue) and IFITM3 (green).  
The levels of IFITM3 in the CD9-negative and CD9-positive EV populations were 
quantified using Imaris Software. Data represent means ± SEM, (n=3).  (C)  EVs 
harvested from 293T-mCherry-IFITM3 cells were fixed, permeabilized, and stained for 
CD63 (blue) and IFITM3 (green).  The levels of IFITM3 in the CD63-negative and 
CD63-positive EV populations were quantified using Imaris Software. Data represent 
means ± SEM, (n=3).  Scale bar = 10 µm. 
 
Tetraspanins and TMPRSS2 Enable EV-Directed Transfers in Mesenchymal Stem 
Cells. 
By using DSP-based approaches, we identified multiple regulators of EV-
mediated cargo transfers in 293T cells.  We predicted that these factors would also 
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control the delivery potentials of therapeutically-relevant EVs.  EVs derived from 
mesenchymal stem cells (MSCs) contain cargoes that inhibit apoptosis, fibrosis, and 
inflammation, making them attractive candidates for many EV-based therapies (58, 
211).  To determine whether tetraspanins and TMPRSS2 enhanced MSC EV delivery 
potentials, EVs from MSCs co-transfected with DSP8 and either tetraspanins or 
TMPRSS2 were applied to MSCs expressing DSP1.  Similar to our results in 293T cells, 
EVs from MSCs overexpressing tetraspanins or TMPRSS2 delivered their DSP8 cargos 
into the target cells, while unstimulated MSC EVs were inert (Figure 21).  These data 
indicated that EV cargo transfer facilitators also enhanced the delivery potential of 
therapeutically-relevant EVs. 
  
 
Figure 21. Tetraspanins and TMPRSS2 Promote EV Cargo Transfer in MSCs. EVs 
collected from conditioned MSC-DSP8 cells were inoculated onto MSC-DSP1 target 
cells.  After 2h at 37oC, DSP8 cargo delivery was measured by its complementation with 
DSP1 into Rluc RLU.  Data bars represent means ± SEM. 
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SYSTEM 3: TEMs as Platforms for Monocyte Cell-Cell Fusions 
Disease-causing Mutations Alter IFITM5 Subcellular Localization. 
Mutations in IFITM5 lead to severe forms of osteogenesis imperfect (179, 180), 
indicating that this IFITM plays a critical role in skeletal homeostasis.  IFITM5 is 
expressed in monocytic osteoclast precursors (182), and is homologous to fusion-
inhibiting IFITMs (183, 184). We thus hypothesized that IFITM5 controls monocyte 
membrane fusion, and that disease-causing mutations dysregulate this activity.  
Considering this hypothesis, we transduced ifitm5 genes into RAW264.7 cells, a 
monocyte/macrophage cell line, using lentiviral vectors.  RAW cells have high levels of 
RANK expression, and fuse into multinucleated osteoclast-like cells upon stimulation 
with soluble RANK ligand (sRANKL) (212).  These membrane fusions occur at the 
termini of cellular extensions (213).  Antiviral IFITMs likely act locally to impede 
membrane fusion (165), so we reasoned that, if IFITM5 controls pre-osteoclast 
membrane fusion, it would localize to pre-osteoclast fusion sites.  Indeed, IFITM5-FLAG 
was expressed on the plasma membrane of transduced cells, and was observed at the 
termini of cellular extensions (Figure 22A).  The distributions of IFITM5 and MALEP-
IFITM5 were identical, but notably IFITM5(S40L) was not present on the cell surface 
(Figure 22A), and instead was observed in the endoplasmic reticulum (Figure 22B).  
This re-localization prevented IFITM5(S40L) from interacting with CD9, a critical 
regulator of pre-osteoclast membrane fusion (97) (Figure 22C).  These results indicated 
that IFITM5 is present at the sites of pre-osteoclast membrane fusion, and suggested 
that the S40L mutation may alter the function of IFITM5. 
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Figure 22.  Localization of IFITM5 in RAW Macrophages. (A) Pre-osteoclasts were 
transduced with retroviral vectors encoding Flag-tagged IFITM5, MALEP-IFITM5, or 
IFITM5(S40L).  4 days post-transduction, unpermeabilized cells were incubated with 
anti-FLAG antibodies (red) and wheat germ agglutinin (blue) to mark the positions of 
Flag-tagged IFITMs and cell plasma membranes, respectively. Hoescht 33258 (grey) 
mark the positions of cell nuclei. Scale bars, 10 μm. (B) Pre-osteoclasts transduced as 
in (A) were permeabilized 4 days post – transduction.  Cells were incubated with anti-
FLAG antibodies (red) and anti-KDEL antibodies (green) to mark the positions of Flag-
tagged IFITMs and ER – localized proteins, respectively. Hoescht 33258 (grey) mark 
the positions of cell nuclei. Scale bars, 10 μm. (C) Pre-osteoclasts transduced as in (A) 
were permeabilized 4 days post – transduction.  Cells were incubated with anti-FLAG 
antibodies (red) and anti-CD9 antibodies (green) to mark the positions of Flag-tagged 
IFITMs and tetraspanin proteins, respectively. Hoescht 33258 (grey) mark the positions 
of cell nuclei. Scale bars, 10 μm. (D) Colocalization of IFITM5 with CD9 was quantified 
from immunofluorescent images of cells stained as in C using Imaris software. Data 
represent means ± SD, (n=3). *, p<0.05. 
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IFITM5 Blocks Osteoclast Formation. 
We predicted that surface-localized IFITM5 could control pre-osteoclast 
membrane fusion, while the intracellular IFITM5(S40L) could not.  We thus stimulated 
ifitm5-transduced RAW cells with sRANKL, and quantified their capacity to fuse into 
multinucleated osteoclasts.  Overexpressed IFITM5 and MALEP-IFITM5 both 
suppressed osteoclast formation and equally reduced the average number of nuclei per 
osteoclast, when compared to a vector-transduced control (Figure 23).  Notably, 
overexpression of IFITM5(S40L) had no effect on osteoclast formation.  This correlates 
with the absence of IFITM5(S40L) on the cell surface (Figures 22 and 23B).  These data 
indicate that IFITM5 has the ability to restrict osteoclastogenesis, and that an OI-
causing mutation destroyed this restriction.  They also suggest that IFITM5 acts locally 
to impede osteoclast formation, similar to how other IFITMs act locally to restrict 
membrane fusion (Figure 19). 
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Figure 23.  Effect of ifitm5 Overexpression on Osteoclast Formation.(A) Pre-
osteoclasts stably expressing IFITM5, MALEP-IFITM5, IFITM5(S40L), or a vector 
control were stimulated to form osteoclasts with 50 ng/mL sRANKL.  5 days later, cells 
were fixed and labeled with anti-FLAG antibodies and wheat germ agglutinin to mark 
the positions of Flag-tagged IFITMs and cell plasma membranes, respectively. Hoescht 
33258 marked the positions of cell nuclei.  The percent of total nuclei in multinucleated 
cells was then quantified from 1000 cells, counted in at least 20 different fields for each 
experiment.  Data represent means ± SD, (n=3). *, p<0.05 when compared to “NO 
IFITM” control. (B) Distribution of multinucleated cells from (A) was quantified from 1000 
cells.  Data represent means ± SD, (n=3).  *, p<0.05 when compared to “NO IFITM” 
control for color – matched condition. (C) Representative images of osteoclast formation 
in the presence of the indicated IFITM.  Anti-FLAG antibodies (red) and wheat germ 
agglutinin (blue) mark the positions of Flag-tagged IFITMs and cell plasma membranes, 
respectively. Hoescht 33258 (grey) mark the positions of cell nuclei.  White arrows mark 
large, multinucleated cells. Scale bars, 15 μm. 
 
IFITM5 Does Not Influence Pre-Osteoclast Differentiation. 
During osteoclastogenesis, monocytes first differentiate into osteoclast precursors 
before fusing together (214), likely because the catalysts of membrane fusion are only 
expressed upon differentiation.  It was therefore possible that IFITM5 restricted pre-
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osteoclast differentiation prior to membrane fusion.  To determine whether IFITM5 
interfered in pre-osteoclast differentiation, we assessed the expression of tartrate-
resistant acid phosphatase (TRAP), a protein highly upregulated in osteoclasts and their 
differentiated precursors (85).  After 5 days of RANKL stimulation, IFITM5-expressing 
RAW cells were fixed and stained for TRAP.  While natural and MALEP-IFITM5 
inhibited osteoclastogenesis, TRAP staining was unaffected by the overexpression of 
these proteins (Figure 24).  These results suggested that IFITM5 does not impede pre-
osteoclast differentiation, and that IFITM5 may act at the level of membrane fusion to 
prevent osteoclast formation. 
 
Figure 24.  Effect of ifitm5 Overexpression on the Expression of Tartrate-
Resistant Acid Phosphatase. Pre-osteoclasts stably expressing the indicated IFITM or 
a vector control were plated on coverslips and stimulated with 50 ng/mL sRANKL.  After 
5 days, cells were fixed and stained for TRAP.  Blue arrows mark large, multinucleated 
osteoclasts. 
 
Amphotericin B Inhibits IFITM5. 
We hypothesized that IFITM5 shared the fusion-inhibiting activities of its antiviral 
paralogs.  Antimycotic polyene compounds, like amphotericin B, interfere with the 
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fusion-inhibiting activities of IFITM3 (215), likely by intercalating into membranes and 
inducing fusion-facilitating membrane curvatures (216, 217).  We therefore 
hypothesized that amphotericin B would also inhibit IFITM5.  RAW cells were thus 
stimulated with sRANKL in the presence or absence of amphotericin B, and the average 
number of nuclei per cell quantified after 4 days.  While amphotericin B had no effect on 
osteoclast formation in the absence of IFITM5 expression, it completely rescued 
osteoclastogenesis in the presence of natural and MALEP-IFITM5 (Figure 25).  Along 
with previous findings (215), these data indicated that amphotericin B is a broad 
inhibitor of all IFITM family members, and suggest that all IFITM proteins operate 
similarly to suppress membrane fusion. 
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Figure 25.  Effect of Amphotericin B on IFITM5 Activity. (A) Pre-osteoclasts stably 
expressing IFITM5, MALEP-IFITM5 or a vector control were stimulated with 50 ng/mL 
sRANKL.  Beginning 24 hours post sRANKL stimulation, cells were incubated for 4 days 
in the presence of 250 ng/mL amphotericin B or DMSO control. Cells were then fixed 
and labeled with anti-FLAG antibodies and wheat germ agglutinin to mark the positions 
of Flag-tagged IFITMs and cell plasma membranes, respectively. Hoescht 33258 
marked the positions of cell nuclei.  The percent of total nuclei in multinucleated cells 
was then quantified from 1000 cells, counted in at least 20 different fields for each 
experiment.  Data represent means ± SD, (n=3).  *, p<0.05. (B) Representative images 
of osteoclast formation in the presence or absence of amphotericin B. Anti-FLAG 
antibodies (red) and wheat germ agglutinin (blue) mark the positions of Flag-tagged 
IFITMs and cell plasma membranes, respectively. Hoescht 33258 (grey) mark the 
positions of cell nuclei. Scale bars, 15 μm. 
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IFITM5 Restricts Membrane Fusion. 
Our results suggested that IFITM5 restricts the membrane fusion-catalyzing 
protein(s) expressed on the surface of pre-osteoclasts.  To directly confirm that IFITM5 
inhibits membrane fusion catalysis, we analyzed the effect of IFITM5 on a known viral 
fusion protein: MERS-S.  To determine whether IFITM5 blocked MERS-S – mediated 
membrane fusion, we transfected DBT cells with DPP4 along with natural or mutant 
IFITM5.  The antiviral IFITM3 was utilized as a positive control.  2 days post-
transfection, cells were inoculated with VSV-based MERSpps.  18 hours later, luciferase 
gene expressions were quantified in target cells as a readout of viral entry.  Notably, 
natural and MALEP-IFITM5 inhibited MERS-S – mediated membrane fusion and viral 
entry, while IFITM5(S40L) did not (Figure 26A).  IFITM5 also restricted cell-cell fusion 
mediated by the Murine Hepatitis Virus (MHV) spike glycoprotein, and this restriction 
was obliterated by amphotericin B (Figure 26B-C).  Together, these results indicate that 
IFITM5 blocks membrane fusions mediated by multiple fusion catalysts, similar to its 
paralogs. 
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Figure 26.  Effect of ifitm5 Overexpression on Viral Membrane Fusion. (A) MERS-
CoV – permissive DBT cells were generated by cotransfection of plasmids encoding 
human DPP4 along with the appropriate IFITM.  48 hours post – transfection, cells were 
inoculated with VSV-based MERS pps for 1 hour, rinsed with serum-free MEM, and 
incubated for an additional 18hrs.  Cells were then lysed and luminescence was 
measured as a readout for viral entry.  Data represent means ± SD, (n=4).  *, p<0.05 
when compared to “NO IFITM” control. (B) Pre-osteoclasts stably expressing the 
appropriate IFITM were infected with GFP – expressing MHV-A59.  2 hours post – 
infection, inoculum was removed and cells were incubated in the presence or absence 
of 250 ng/mL amphotericin B. After 16 hours, cells were then fixed and labeled with 
Hoeschst 33258 to mark cell nuclei. The percent of GFP+ nuclei in multinucleated cells 
was then quantified from 1000 cells.  Data represent means ± SD, (n=3).  *, p<0.05. 
(C)Representative images of cells from (B). GFP expression marks infected cells, while 
Hoescht 33258 (blue) marks the positions of cell nuclei. White arrows mark 
multinucleated cells. 
 
83 
 
 
 
CD9 Overexpression Rescues Osteoclast Formation in the Presence of IFITM5. 
IFITMs control tetraspanin localization and their interactions with other proteins.  IFITM5 
disturbs interactions between CD9 and CD81 (136), tetraspanins critical for 
osteoclastogenesis.  We hypothesized that IFITM5 may suppress osteoclast membrane 
fusion by disrupting the activities of these critical tetraspanins.  We therefore 
overexpressed CD9 in RAW cells, along with natural or mutant IFITM5, and assessed 
the ability of these cells to fuse into osteoclasts.  Notably, overexpressed CD9 
accumulated in large puncta on the cell surface (Figure 27A), and rescued osteoclast 
formation in the presence of IFITM5 (Figure 27B-C).  These data indicated that CD9 
overexpression overcame IFITM5 inhibitory activities, and suggested that IFITM5 acts 
through CD9 to suppress membrane fusion. 
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Figure 27.  Effect of CD9 Overexpression on IFITM5 Activity. (A) Pre-osteoclasts 
were transduced with CD9 or a vector control.  4 days later, cells were fixed and labeled 
with anti-CD9 (green) and Hoeschest 33258 (grey). Scale bars, 10 μm.  (B) Pre-
osteoclasts stably expressing the indicated IFITM or a vector control were transduced 
with a vector control or CD9. 2 days post – transduction, cells were stimulated with 50 
ng/mL sRANKL for 4 days. Cells were then fixed and labeled with anti-FLAG, 
fluorescently labeled wheat germ agglutinin and Hoeschst 33258 to mark Flag-tagged 
IFITMs, cell plasma membranes and nuclei, respectively. The percent of total nuclei in 
multinucleated cells was then quantified from 1000 cells, counted in at least 20 different 
fields for each experiment.  Data represent means ± SD, (n=3).  *, p<0.05. (C) 
Representative images of cells from (B).  Anti-FLAG antibodies (green) and wheat germ 
agglutinin (red) mark the positions of Flag-tagged IFITMs and cell plasma membranes, 
respectively. Hoescht 33258 (grey) mark the positions of cell nuclei. Scale bars, 15 μm. 
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CHAPTER FOUR 
DISCUSSION 
Summary of Data 
 We sought to characterize the roles of tetraspanins in constructing virus, EV, and 
cell membrane fusion platforms.  Our results indicate that TEMs act as platforms for a 
wide range of membrane fusion processes, illustrating how membrane dynamics in 
diverse environments are controlled by a common set of elements.  These elements 
include the tetraspanins themselves, which can facilitate and enable membrane fusions 
(Figures 1, 9-10, 13-15), as well as IFITMs, which incorporate into TEMs to inhibit 
membrane mergers (Figures 17-19, and 23).   
First, we sought to determine whether MERS-CoV utilizes TEMs as fusion 
platforms in cell culture and in vivo.  We determined that CD9 was critical for MERS-
CoV entry in cell culture (Figure 7), and was the tetraspanin partner of the MERS-CoV 
receptor DPP4 (Figure 8) (148).  CD9 acted to link DPP4 with the protease TMPRSS2, 
thereby facilitating MERS-S proteolysis and viral entry (Figure 9).  We then developed 
an Ad5-based approach to render mouse lung cells permissive to infection while also 
transiently overexpressing or depleting candidate viral entry factors.  Using this 
approach, we demonstrated for the first time that MERS-CoVs utilize TEMs as fusion 
platforms in vivo (Figure 10).  Thus, MERS-CoV fusion platforms include at least three 
factors: the receptor DPP4, the tetraspanin CD9, and the protease TMPRSS2.
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Next, we developed the first quantitative assay to monitor EV-cell membrane 
fusions and cargo deliveries (Figure 11).  This assay relied on the transfer of reporter 
protein fragments between cell cytosols.  Using this method, we were the first to 
determine that membrane fusion drives the delivery of luminal EV cargos into cell 
cytosols (Figure 12).  We also determined that EV-incorporated tetraspanins enabled 
EV cargo deliveries post-binding, likely at the level of membrane fusion (Figure 15).  
IFITM3, in contrast, incorporated into tetraspanin-containing EVs to restrict EV 
fusogenicity (Figures 17-19).  Together, these data indicate that TEMs act as platforms 
for EV membrane fusions.   
We also found that EVs vary in their cargo delivery potentials, with delivery-
competent EVs comprising only a small subset of vesicles released by the cell.  
Transfer-competent EVs are enriched in tetraspanins (Figure 14), and are targeted by 
IFITM3 (Figure 20).  Deliveries by these transfer-competent EVs were only detectable 
upon EV producer cell modification, at least in the context of 293T cells and MSCs 
(Figures 13, 16, and 21).   
Finally, we found that TEMs also control monocyte membrane fusion, with the 
tetraspanin CD9 enhancing (Figure 27), and the bone-specific IFITM5 inhibiting (Figure 
23), monocyte multinucleation and osteoclast formation.  We are the first to determine 
that the constitutively expressed IFITM5 shares the fusion-inhibiting activities of the IFN-
induced IFITMs, and that IFITM5 acts through CD9 to prevent membrane mergers 
(Figure 27).  CD9 overexpression rendered IFITM5 inert, as did treatment with 
amphotericin B (Figure 25), suggesting that IFITMs act through tetraspanins to alter 
membrane curvature and fluidity in ways that render them fusion-incompetent. Disease-
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causing mutations to IFITM5 differentially effected its fusion-inhibiting activities, with one 
mutant, MALEP-IFITM5, retaining its fusion-inhibiting activities, while another mutant, 
IFITM5(S40L) was inert (Figure 23).  These results are the first to identify functional 
differences between mutant and natural IFITM5s, and they suggest that distinct 
mutations in IFITM5 cause disparate forms of OI. 
Overall, these results indicate that a variety of membrane fusion reactions, 
across different environments, all rely on a common set of regulators.  These regulators 
are concentrated into TEMs, likely by the tetraspanins themselves.  Tetraspanins, 
therefore, may be central to constructing all extra-cellular platforms for membrane 
fusion catalysis. 
Requirement of CD9 during MERS-CoV Early Entry 
 Our findings indicate that TEMs are platforms for MERS-CoV proteolysis and 
viral entry.  CD9 is a central component in this fusion platform, as it links DPP4 with 
TMPRSS2 (Figure 9).  Close proximity between DPP4 and CoV activating proteases is 
likely required for early, TMPR-mediated viral entry.  This is because only DPP4-bound 
CoV S proteins are susceptible to productive, fusion-facilitating proteolytic cleavages 
(24), and because cell surface proteases are likely concentrated TEMs (Figure 8) (28).  
Additional findings by Dr. James Earnest have confirmed that CD9 is specifically used in 
early, but not late, CoV entry pathways (218).  As discussed in Chapter 1, this could be 
because proteolytic triggering during late entry is catalyzed by soluble cathepsins (29), 
which may not require tetraspanins to encounter receptor-bound CoV-S proteins.  It is 
therefore notable that CD9 is so critical for MERS-CoV infections in the mouse lung 
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(Figure 10).  These results suggest that MERS-CoVs have evolved to preferentially 
utilize early entry routes in vivo.   
It is unclear why MERS-CoVs have such a preference for early entry.  
Possibilities include low levels of cathepsins in lung cells, or alternatively the preference 
to avoid endosome-localized antiviral factors, like the IFITMs (165).  It also is unclear 
why CoVs maintain the ability to utilize late entry routes.  Importantly, it is possible that 
these late entry pathways are simply byproducts of culturing CoVs in commonly-used 
cell lines cells.  Some of these cell lines have very low levels of cell surface serine 
proteases (24), and CoVs preferentially use late entry routes to infect these cells.  
Future investigations into CoV entry pathways would likely benefit from utilizing cells 
with high surface protease expression. 
Selective Use of TMPRSS2 by MERS-CoVs to Infect the Lung 
Our results using Ad5 vectors indicate that MERS-CoV relies heavily on a single 
protease, TMPRSS2, to enter mouse lung cells.  While previous studies have 
highlighted the importance of serine proteases in CoV lung infections (33), cell culture 
studies suggest that CoVs can utilize a variety of proteases to trigger membrane fusion 
catalysis, including TMPRs (35), pro-protein convertases (219), and metalloproteases 
(220).  Many of these proteases also localize to TEMs.  Presumably, DPP4-bound 
MERS-CoVs would be able to engage several different proteases to facilitate entry.  
This, however, is not the case in mouse lungs, as viral titers were significantly reduced 
by depleting just one protease (Figure 10).  While these reasons for this specificity are 
unclear, it may be due to high levels of TMPRSS2 in lung epithelial cells, or due to close 
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interaction between CD9 and an unidentified tetraspanin that presumably aggregates 
TMPRSS2 into TEMs (218).   
Tetraspanins in the Entry of Other CoVs 
In addition to MERS-CoV, we have determined that the CoV 229E also utilizes 
CD9 during viral entry (218).  Notably, however, not all CoVs utilize CD9 to facilitate 
membrane fusion, as SARS-CoV (Figure 7) and murine hepatitis virus (MHV) (218) 
were unaffected by CD9 depletion.  One possible explanation is that SARS and MHV 
have evolved to rely on other tetraspanins for entry.  Antibodies targeting the 
tetraspanins CD9, CD81, and CD63, which likely act to rigidify TEMs through 
tetraspanin crosslinking, inhibit the entry of all CoVs, supporting this hypothesis (28).  In 
addition, many CoV receptors, including the SARS receptor ACE2 and MHV receptor 
CEACAM, preferentially localize to TEMs (28, 218).  It is intriguing to speculate why 
CoVs have come to utilize TEMs as proteolytic priming platforms.  Alternative proteolytic 
pathways do exist.  For example, CoVs can be cleaved by extracellular proteases in the 
lung parenchyma (221).  CoVs could theoretically evolve structures that allow for 
proteolytic “priming” before a receptor-dependent “triggering” event.  It is likely, 
however, that proteolyzed CoV-S proteins would be unstable, and susceptible to 
inactivation.  This may be the reason CoV-S proteins have evolved to restrict their 
proteolysis to receptor-bearing target cell membranes.  Further investigation, however, 
is required to determine whether all CoVs depend on particular tetraspanins, and 
proteases, to enter cells. 
 
 
90 
 
 
 
Utilizing Recombinant Adenoviruses for Gene Knockdown 
We sought to determine whether MERS-CoV utilizes TEMs as platform for viral 
infection in the lung.  This was accomplished through the generation of recombinant 
adenoviruses that express both shRNAs silencing genes of interest as well as the 
MERS-CoV receptor hDPP4.  Using these dual-expressing Ad5 vectors, our 
collaborators were able to both render mouse lung cells permissive to MERS-CoV 
infection while also depleting candidate CoV entry factors from the same cells (Figure 
10).  This system overcame the time-consuming requirements of generating transgenic 
or knockout mice, making it an efficient was to rapidly identify viral entry factors in the 
mouse lung.  Ad5 vectors also only acted on transduced cells, likely diminishing any off-
target effects from gene knockdown or overexpression.  This approach can be applied 
to any viral system where cells must be rendered permissive to infection, and we 
speculate that many will use this technology in the future to identify factors critical for 
viral replication and transmission. 
TEMs as General Platforms for Viral Entry 
 Findings from our lab and others indicate that tetraspanins promote the entry of 
multiple viruses, including coronaviruses (Figures 7, 9-10) (28), human cytomegalovirus 
(HCMV) (139), human papilloma virus (HPV) (141, 145), influenza virus (IAV) (28, 142), 
hepatitis C virus (HCV) (138, 146, 147), lujo virus (140), and several alphaviruses (143, 
144).  In many of these cases, tetraspanins promote viral entry by regulating the 
composition of TEMs.  For example, IAV hemagglutinin is proteolyzed in TEMs, similar 
to CoVs (28).  The tetraspanin CD81 is critical for viral entry (142), suggesting that this 
tetraspanin may bring IAV-activating proteases into close proximity with sialate 
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receptors.  As discussed in Chapter 1, while CD81 is the primary receptor for HCV 
(138), it also coalesces HCV coreceptors into a complex required for endocytosis (146, 
147).  CD151 operates in a similar manner to aggregate HPV coreceptors and drive 
endocytosis of receptor-bound HPVs (141, 145).  We predict that many viruses have 
evolved to utilize TEM-resident entry factors due to their close proximity, and thus rely 
on tetraspanins to maintain these entry platforms. 
Mechanisms of EV Cargo Delivery 
While the phenotypic effects of EV-directed cargo transfers are readily 
documented (48, 51), the regulation and efficiency of this delivery process was largely 
unknown.  Here we developed new approaches to investigate EV-mediated membrane 
fusions and cargo transmissions.  These approaches rely on the transfer of split reporter 
proteins between cell and vesicle cytosols.  Using these approaches, we discovered 
that TEMs regulate EV cargo deliveries and act as platforms for EV-cell fusions. EV 
cargo delivery potentials correlated with TEM composition.  We found that the 
tetraspanins CD9, CD63, and CD81 all enabled cargo deliveries at some stage post-
binding, likely at the level of membrane fusion (Figure 15).  A bona-fide fusion catalyst, 
the viral fusion protein VSVG, also bestowed EVs with transfer-competence (Figure 12), 
indicating that membrane fusions can drive EV cargo transfers.   
Tetraspanins may enable EV-cell fusions by generating positive membrane 
curvatures on both EV and cell membranes (120, 149), thereby bringing them into close 
proximity.  Alternatively, these tetraspanins may concentrate unidentified EV fusion 
machinery in TEMs, thereby facilitating their interactions similar to how CD9 aggregates 
MERS-CoV entry factors (Figure 9).  It is notable that tetraspanins regulate the 
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localization of fusion – promoting lipids.  CD81, for example, interacts directly with 
cholesterol (116), and also facilitates the externalization of the fusion – promoting lipid 
phosphatidylserine (222).  In addition, individual tetraspanins interact with distinct 
integrins that may also bring membranes into close proximity to allow for membrane 
merger (130).  Finally, it is possible that tetraspanins interact with true membrane fusion 
catalysts.  Notably, some endogenous retroviral fusion proteins incorporate into EVs 
(223), though whether these fusogens interact with tetraspanins is unclear.  Comparing 
delivery-competent and –incompetent EV subsets by lipidomic and proteomic analyses 
may provide additional insights into the architecture of EV-cell fusion platforms. 
Inhibition of EV Cargo Delivery 
In contrast to the delivery-facilitating tetraspanins, IFN stimulated the ISG IFITM3 
to incorporate into EVs and impede cargo deliveries (Figure 17).  Our in vitro EV-virus 
and EV-EV fusion assays indicate that IFITM3 functions on EVs to inhibit membrane 
fusion and cargo delivery (Figure 19). These results, along with previous findings that 
IFITM3 blocks virus-cell membrane fusions (162, 164), strongly suggest that EVs deliver 
hydrophilic macromolecules into the cytoplasm via membrane fusion. 
Our results indicate that inhibition of cargo transfer was more potent when 
IFITM3 was present in EVs, rather than in target cells (Figure 18).  This could be due to 
high concentrations of IFITM3 on tetraspanin-containing EVs, which might be mediated 
by IFITM-tetraspanin interactions (136, 172).  Indeed, while IFITM3 was present on only 
~20% of 293T EVs, it incorporated into ~45% of tetraspanin-containing vesicles (Figure 
20), supporting this hypothesis.  Interactions with tetraspanins may lead to the formation 
of multimeric IFITM3 networks, which could be essential for membrane fusion inhibition 
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(158).  Alternatively, EVs may not rely on TEMs on target cells to catalyze membrane 
fusion, thereby avoiding membrane platforms with high IFITM3 concentrations.  
Tetraspanin overexpression in target cells did not permit EV cargo transfers (Figure 13), 
consistant with this hypothesis.  Intriguingly, several enveloped viruses can also evade 
cellular IFITMs (163), and further investigation is required to determine whether IFITM 
sensitivity correlates with TEM utilization during virus or EV entry. 
Potential Implications of IFITM-Mediated Inhibition of EV Fusion 
IFNs and IFITMs are traditionally thought of as antiviral agents, and we speculate 
that these antiviral activities may extend to EV-incorporated IFITMs.  EVs can transfer 
viral proteins and nucleic acids between cells (59, 224), and incorporated IFITMs would 
suppress the dissemination of these viral factors (Figurs 17-19).  Similarly, EVs can also 
transmit pathogenic protein aggregates like prions and α-synuclein (62, 63), as well as 
oncogenic proteins and nucleic acids between cells (48).  We speculate IFNs and 
IFITMs prevent the dissemination of many harmful cargos.   
Intriguingly, EVs can also ferry pro-inflammatory molecules, the very factors that 
induce IFNs and IFITMs, between cells. For example, stromal cell EVs can transfer pro-
inflammatory RNAs to breast cancer cells, leading to RIG-I activation and the production 
of both IFNs and more pro-inflammatory RNAs (225).  EVs can also transmit 
lipopolysaccharide (LPS)-induced microRNA-155, which sensitizes cells to EV target 
cells to subsequent LPS-induced signaling (51).  These positive-feedback loops of pro-
inflammatory responses may be tempered by IFITMs, which are induced by both IFN 
and LPS (226).  This would prevent runaway inflammation and promote the return to 
homeostatic conditions.  Notably, even in the absence of inflammation or disease, EVs 
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and IFITMs control lymphocyte activation (50, 227), skeletal homeostasis (53, 179), and 
tumor growth and metastasis (48, 176).  It is possible that IFITMs and EVs act in 
concert to control these biological processes by precisely tuning intercellular 
communications. 
While we have focused on EV luminal cargos, whose delivery requires EV-cell 
fusion, it is notable that fusion-incompetent vesicles could also play critical roles in 
intercellular communication.  These roles include antigen cross-presentation (50), 
protein turnover (44), and signal transduction mediated by receptor binding.  IFITM3 
and other fusion inhibitors could be utilized to distinguish between fusion -dependent 
and –independent EV activities. 
Limitations to EV Cargo Transfer 
There were profound limitations to EV-directed cargo transfers.  Indeed, transfers 
were undetectable unless producer cells were stimulated to hyper-secrete EVs, some of 
which were transfer-competent (Figures 13, 16, and 21).  Still, only a small fraction 
(1/10,000th) of secreted DSPs were successfully transferred and registered in target 
cells (Figure 15).  These inefficiencies in EV-directed transfers may be due to low EV 
adherence to target cells, since only 0.3% EVs bound to 293T cells after 2 hours at 
13°C (Figure 15).  Additional transfer inefficiencies may also derive from the small 
fraction of EVs that are indeed transfer competent.  Under conditions where IFITM3 
blocked ~85% of cargo transfers (Figure 18), only ~20% of EVs contained IFITM3 
(Figure 20).  Given that IFITM3 likely acts locally to block membrane mergers (165) 
(Figure 19), these results suggest that only a small subset of EVs released from 293T 
cells is transfer competent.  These results extend the concept of EV heterogeneity to 
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the level of EV fusogenicity and cargo delivery potential.  Further investigations in 
additional cell types and conditions are required to determine whether EVs also have 
low transfer potential in vivo, where long-distance EV-directed transmissions have been 
documented (78). 
 Membrane Fusion Inhibition as a Shared Function of IFITMs 
 Skeletal maintenance requires both bone-depositing mesenchymal osteoblasts 
and bone-resorbing hematopoietic osteoclasts (228).  Dysregulation of osteoclast 
activity can lead to complications including osteopenia and osteoporosis (85).  
Developing new therapies for these diseases will significantly benefit from elucidating 
the molecular mechanisms of monocyte membrane fusion.  Our results indicate that 
monocytic pre-osteoclast membrane fusions occur in TEMs.  The tetraspanin CD9 
promoted pre-osteoclast multinucleation (Figure 27), while IFITM5 inhibited this process 
(Figure 23).  IFITM5 did not prevent osteoclast differentiation (Figure 24), and blocked 
virus-catalyzed membrane fusions (Figure 26), strongly suggesting that IFITM5 acts at 
the level of membrane fusion to suppress osteoclastogenesis.  Membrane fusion 
inhibition is thus a shared activity across both interferon-induced and constitutively 
expressed IFITMs.  Notably, the IFITM protein family is ancient, and IFITM5 is 
homologous with evolutionarily distant IFITM orthologs (183, 184).  Fusion-inhibiting 
IFITM-like proteins are also present in mycobateria (229), leading us to speculate that 
the primordial function of IFITMs was to control membrane mergers. 
In addition to IFITM5, it is possible that other IFITMs also control monocyte 
membrane fusion.  Indeed, monocytes can express IFITMs 1, 2, and 3 (230), possibly 
due to tonic IFN signaling.  While it is unclear whether IFN-induced IFITMs control 
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osteoclastogenesis, intriguingly mice deficient in IFN-β signaling show symptoms of 
enhanced bone resorption and osteoclast activity (231).  The role of IFN-induced 
IFITMs in suppressing monocyte fusions may be even more relevant in the lung, where 
monocytes fuse into giant cell macrophages to defend against foreign materials and 
pathogens (90–92).  We hypothesize that IFITMs generally act to temper monocyte 
membrane fusions across different tissues. 
Functional Relationship between IFITMs and Tetraspanins 
Our results suggest that IFITM5 acts through CD9 to block monocyte fusion, as 
CD9 overexpression overcame IFITM5 inhibition (Figure 27).  In addition, IFITM3 
preferentially incorporated into tetraspanin-enriched EVs to suppress EV-cell fusion and 
cargo transfer (Figures 19 -20).  It is possible that IFITMs suppress membrane fusion by 
disrupting critical interactions between tetraspanins and their protein partners.  IFITM5 
disrupts interactions between CD9 and CD81 (136), and IFITM1 disrupts tetraspanin 
interactions to inhibit virus-cell fusion (172), supporting this speculation.  Tetraspanins 
induce positive membrane curvatures (120, 149), and it is possible that these 
curvatures require tetraspanin-tetraspanin interactions.  By disrupting these interactions, 
IFITMs may render membranes fusion-incompetent.  Alternatively, IFITMs may rely on 
tetraspanins to localize to sites of membrane fusion.  Overexpressed CD9 may not 
localize specifically to pre-osteoclast fusion platforms, and could thus dilute IFITM5 
proteins away from pre-osteoclast fusion sites.  Further investigation is required to 
determine whether disrupting protein-protein interactions in TEMs is a common 
mechanism by which IFITMs prevent membrane mergers, or whether tetraspanins are 
instead essential to concentrate IFITMs at sites of membrane fusion. 
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Amphotericin B and IFITM-Mediated Fusion Inhibition 
In addition to CD9 overexpression, amphotericin B treatment also inhibited 
IFITM5 (Figure 25).  Amphotericin B and other polyene compounds integrate into the 
outer leaflet of lipid bilayers, increasing membrane fluidity and potentially causing 
outward bending of the plasma membrane away from the cytosol (216, 217, 232).  By 
integrating into outer membrane leaflets, amphotericin B may induce positive membrane 
curvatures that compete against the negative-curving IFITMs (Figure 6).  They also 
decrease the relative amount of inward-curving sterols in membranes (233, 234), which 
may contribute to their activities.  It is notably that amphotericin B and related polyenes 
are used therapeutically as antifungals.  Given their ability to inhibit IFITMs and thereby 
promote membrane fusion (215) (Figure 25), it is possible that polyenes could be 
applied to conditions of excess bone deposition, including patients harboring MALEP-
IFITM5 and those suffering from osteopenia. 
Potential Heterogeneity in OI Type V Pathologies 
 Our results suggest that dysregulated osteoclastogenesis contributes to OI type 
V (Figure 23).  Notably, our results also suggest that distinct IFITM5 mutations may 
cause different forms of OI type V.  While MALEP-IFITM5 blocked membrane fusion 
similarly to its natural counterpart, IFITM5(S40L) was inert.  Patients with the S40L 
mutation have greater bone resorption and lower bone mineral densities than patients 
expressing MALEP-IFITM5 (189), suggesting that IFITM5(S40L) patients may have 
overabundant osteoclasts (180).  Patients expressing MALEP-IFITM5, in contrast, often 
have excess bone deposits including hyperplastic calluses, hyperdense metaphyseal 
bands, and interosseous calcification (179).  This correlates with MALEP-IFITM5 fusion 
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inhibition (Figure 23).  MALEP-IFITM5, however, could dysregulate skeletal 
maintenance in other ways, since natural IFITM5 can suppress membrane fusions to a 
similar extent.  Distinguishing between the diseases caused by IFITM5 mutants may 
lead to the development of distinct therapies for these forms of OI type V. 
Identifying Additional Membrane Fusion Catalysts and Regulators 
We are likely just beginning to identify regulators of EV-cell and cell-cell 
membrane fusion.  Enveloped virus membrane fusions are controlled at the level of the 
target cell by cellular receptors, cations, proteases, temperature, pH, and membrane 
lipid composition (5).  We have determined that tetraspanins, TMPRSS2, and 
endosome acidification control EV cargo transfers at the level of the EV producer cell 
(Figures 13-16).  However, none of these factors regulated EV-cell membrane fusions 
when applied to target cells.  Thus target cell factors regulating EV-cell membrane 
fusion remain unclear.  We speculate that virus, cell and EV membrane fusions share 
many common regulators in both producer and target cells.  DSP-based approaches 
could potentially be used in high-throughput screens to identify EV, virus and cell fusion 
enhancers and suppressors.  These screens could be applied to many therapeutically-
relevant cell types, including MSCs and monocytic osteoclast precursors.  By enhancing 
and suppressing EV and cell membrane fusion potentials in therapy models, we may 
uncover how membrane fusions control disease. 
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